1
2
3
4
5 **Pathogen infection and cholesterol deficiency activate the *C. elegans* p38 immune**
6 **pathway through a TIR-1/SARM1 phase transition**
7
8

9 **Nicholas D. Peterson^{1,#}, Janneke D. Icks^{2,#}, J. Elizabeth Salisbury¹, Tomás Rodríguez³,**
10 **Paul R. Thompson^{2,*}, Read Pukkila-Worley^{1,*}**
11

12 ¹Program in Innate Immunity, Division of Infectious Diseases and Immunology, ²Program in
13 Chemical Biology, ³RNA Therapeutics Institute, University of Massachusetts Chan Medical
14 School, Worcester, MA, 01655, United States of America
15

16 #These authors contributed equally to this work
17

18 *Correspondence may be addressed to Read Pukkila-Worley (Read.Pukkila-
19 Worley@umassmed.edu, @RPWlab) or Paul Thompson (Paul.Thompson@umassmed.edu,
20 @pthompsn1018)
21

22 Classification: Major: Biological Sciences; Minor: Immunology and Inflammation
23

24 Keywords: p38 pathway; cholesterol; TIR-1/SARM1; phase transition

ABSTRACT

Intracellular signaling regulators can be concentrated into membrane-free, higher-ordered protein assemblies to initiate protective responses during stress — a process known as phase transition. Here, we show that a phase transition of the *Caenorhabditis elegans* Toll/interleukin-1 receptor domain protein (TIR-1), an NAD⁺ glycohydrolase homologous to mammalian sterile alpha and TIR motif-containing 1 (SARM1), underlies p38 PMK-1 immune pathway activation in *C. elegans* intestinal epithelial cells. Through visualization of fluorescently labeled TIR-1/SARM1 protein, we demonstrate that physiologic stresses, both pathogen and non-pathogen, induce multimerization of TIR-1/SARM1 into visible puncta within intestinal epithelial cells. *In vitro* enzyme kinetic analyses revealed that, like mammalian SARM1, the NAD⁺ glycohydrolase activity of *C. elegans* TIR-1 is dramatically potentiated by protein oligomerization and a phase transition. Accordingly, *C. elegans* with genetic mutations that specifically block either multimerization or the NAD⁺ glycohydrolase activity of TIR-1/SARM1 fail to induce p38 PMK phosphorylation, are unable to increase immune effector expression, and are dramatically susceptible to bacterial infection. Finally, we demonstrate that a loss-of-function mutation in *nhr-8*, which alters cholesterol metabolism and is used to study conditions of sterol deficiency, causes TIR-1/SARM1 to oligomerize into puncta in intestinal epithelial cells. Cholesterol scarcity increases p38 PMK-1 phosphorylation, primes immune effector induction in a manner that requires TIR-1/SARM1 oligomerization and its intrinsic NAD⁺ glycohydrolase activity, and reduces pathogen accumulation in the intestine during a subsequent infection. These data reveal a new adaptive response that allows a metazoan host to anticipate pathogen threats during cholesterol deprivation, a time of relative susceptibility to infection. Thus, a phase transition of TIR-1/SARM1 as a prerequisite for its NAD⁺ glycohydrolase activity is strongly conserved across millions of years of evolution and is essential for diverse physiological processes in multiple cell types.

INTRODUCTION

The p38 mitogen-activated protein kinase (MAPK) pathway is a key regulator of stress responses and innate immune defenses in metazoans. The *C. elegans* p38 homolog PMK-1 is part of a classic MAPK signaling cascade that is activated by the MAPKKK NSY-1 and MAPKK SEK-1, which are the nematode homologs of mammalian ASK and MKK3/6, respectively (1). As in mammals, the *C. elegans* p38 PMK-1 pathway regulates the expression of secreted innate immune effectors and is required for survival during pathogen infection (1-4). However, the mechanisms that activate the NSY-1/SEK-1/p38 PMK-1 signaling cassette in *C. elegans* intestinal epithelial cells are poorly defined.

Toll/interleukin-1 receptor (TIR) domain-containing proteins serve essential functions in both animal and plant immunity (5-7). In mammals, Toll-like receptors (TLRs) and downstream adaptor proteins contain TIR domains, which transduce intracellular signals upon pathway activation (8). Nucleotide-binding leucine-rich repeat (NLR) proteins in plants also contain TIR domains, which activate host defenses following recognition of pathogen-derived effector proteins (9). In *C. elegans*, TIR-1, the homolog of mammalian sterile alpha and TIR motif-containing 1 (SARM1), acts upstream of NSY-1/ASK to control p38 PMK-1 activation (10, 11). Interestingly, TIR-1/SARM1 is unique among animal and plant TIR domain-containing proteins in that it is an enzyme, which cleaves nicotinamide adenine dinucleotide (NAD⁺) (12, 13). The NAD⁺ glycohydrolase activity of TIR is activated upon oligomerization into a multimeric protein complex (14). NAD⁺ depletion in this manner promotes cell death in plants during pathogen infection and triggers axonal degeneration following neuronal injury (15, 16). However, it is not known whether the NAD⁺ glycohydrolase activity of TIR is also required for immune function in metazoans.

Intracellular signaling regulators can be compartmentalized into membrane-less, higher-ordered protein assemblies with liquid droplet-like properties (17-23). Cytoplasmic de-mixing or phase transition of proteins in this manner concentrates signaling regulators to facilitate rapid

and specific activation of protective defenses during stress (17, 18, 24). Interestingly, human SARM1 oligomerizes and undergoes a phase transition, which enhances its intrinsic NAD⁺ glycohydrolase activity (25). Induced multimerization of *C. elegans* TIR-1/SARM1 in neurons also correlated with enhanced axonal degeneration (25). Here, we show that a phase transition and NAD⁺ glycohydrolase activity of TIR-1/SARM1 is required for p38 PMK-1 immune pathway activation and pathogen resistance in *C. elegans*. We labeled the TIR-1/SARM1 protein with a fluorescent tag at its genomic locus and demonstrated that TIR-1/SARM1 forms visible puncta within the intestine in response to physiologic stimuli, including both pathogen infection and cholesterol deficiency. By promoting multimerization of TIR-1/SARM1 with macromolecular crowding agents *in vitro*, we demonstrate that a phase transition is required for the catalytic activity of TIR-1/SARM1. Accordingly, TIR-1/SARM1 containing mutations that either specifically prevent the phase transition or impair NAD⁺ hydrolysis shows decreased enzymatic activity *in vitro*. *C. elegans* carrying these same mutations, edited into the genome using CRISPR/Cas9, fail to induce p38 PMK phosphorylation, are unable to upregulate immune effector expression, and have enhanced susceptibility to bacterial infection.

We also report that a loss-of-function mutation in *nhr-8*, which alters cholesterol metabolism and is used to study conditions of sterol deficiency (26), induces TIR-1/SARM1 oligomerization and p38 PMK-1 pathway activation. *C. elegans* lacks the ability to synthesize cholesterol *de novo* and must acquire dietary sterols from the environment to support multiple aspects of cellular physiology, including development, fecundity, lifespan, and resistance against pathogen infection (27-33). Some, but not all, *C. elegans* larvae that encounter sterol-scarce environments enter an alternative developmental program, called dauer diapause, to promote animal survival (34-38). Here, we show that *C. elegans* larvae that do not enter dauer diapause in an environment devoid of dietary sterols adapt by promoting oligomerization of TIR-1/SARM1 *in vivo* to activate the p38 PMK-1 innate immune pathway through its intrinsic NAD⁺ glycohydrolase activity. Priming p38 pathway activation in this manner augments immune

102 effector expression during a subsequent bacterial infection and reduces pathogen accumulation
103 in the intestine. Thus, we propose that activation of the p38 PMK-1 pathway during conditions of
104 low cholesterol availability is an adaptive response to preempt pathogen attack during a time of
105 relative vulnerability to infection.

RESULTS

Multimerization of TIR-1/SARM1 and its intrinsic NAD⁺ glycohydrolase activity are required for activation of the p38 PMK-1 innate immune pathway during pathogen infection.

To determine if *C. elegans* TIR-1/SARM1 multimerizes to activate the p38 PMK-1 innate immune pathway, we used CRISPR/Cas9 to insert the fluorescent protein wrmScarlet at the C-terminus of the endogenous *C. elegans tir-1* locus, which labeled all *tir-1* isoforms. In uninfected animals, TIR-1::wrmScarlet is barely detectable in intestinal epithelial cells (Fig. 1A). However, *P. aeruginosa* infection caused TIR-1::wrmScarlet to multimerize into visible puncta within intestinal epithelial cells (Fig. 1A and 1B). We distinguished TIR-1::wrmScarlet puncta from autofluorescent gut granules by comparing images in the red and green fluorescence channels. TIR-1::wrmScarlet puncta are those that are seen in the red, but not the green fluorescence channel (arrowheads in Fig. 1A), as opposed to gut granules, which can be seen in both channels (asterisks in Fig. 1A).

C. elegans TIR-1 protein has three characterized domains: a Heat/Armadillo repeat domain, a sterile alpha motif (SAM) domain, and a Toll-interleukin receptor (TIR) domain (39) (Fig. 1C). *C. elegans* TIR-1 oligomerizes *in vitro* through interactions of its SAM domains (14). We used CRISPR-Cas9 to delete both SAM domains in *tir-1* (*tir-1*^{ΔSAM}) and to generate point mutants in two residues within the *C. elegans* TIR domain that are important for the self-association and activity of mammalian SARM1 (*C. elegans tir-1*^{G747P} and *tir-1*^{H833A}) (14) (Fig. 1D). The *C. elegans tir-1*^{ΔSAM}, *tir-1*^{G747P} and *tir-1*^{H833A} mutants prevented activation of the p38 PMK-1-dependent immune reporter T24B8.5p::gfp in animals infected with *P. aeruginosa* (Fig. 1D). Consistent with these data, the *tir-1*^{ΔSAM}, *tir-1*^{G747P} and *tir-1*^{H833A} mutants have reduced levels of active, phosphorylated p38 PMK-1, equivalent to the *tir-1(qd4)* null allele (40) (Figs. 1E

and 1F). Additionally, these mutants are each markedly hypersusceptible to *P. aeruginosa* infection (Fig. 1G).

The TIR domain of *C. elegans*, TIR-1, and its mammalian homolog, SARM1, possess intrinsic NADase activity (12, 14, 41). Importantly, oligomerization of mammalian SARM1 and *C. elegans* TIR-1 is required for maximal NADase activity *in vitro* (14). The NADase activity in the TIR domain of mammalian SARM1 requires a putative catalytic glutamate residue (12). We used CRISPR-Cas9 to mutate the homologous glutamate in *C. elegans tir-1* (*tir-1*^{E788A}) and found that it was required for the immunostimulatory activity of *tir-1* – *tir-1*^{E788A} mutants do not induce T24B8.5p::gfp following *P. aeruginosa* infection (Fig. 1D), had less active, phosphorylated p38 PMK-1 (Figs. 1E and 1F), and were more susceptible to *P. aeruginosa* infection (Fig. 1G). We confirmed that *tir-1*^{E788A}, *tir-1*^{ΔSAM} and *tir-1*^{G747P} mutants are translated and not degraded by introducing a 3xFLAG tag at the C-terminus of each mutant using CRISPR-Cas9 (Fig. 1 – figure supplements 1A and 1B) and probing for epitope-tagged mutant protein in western blots with an anti-FLAG antibody (Fig. 1 – figure supplement 1A). In addition, the 3xFLAG-tagged wild-type TIR-1 expressed T24B8.5p::gfp, but the tagged mutant TIR-1 proteins did not (Fig. 1 – figure supplement 1B). Collectively, these data demonstrate that multimerization of TIR-1 and its intrinsic NADase activity are required to activate the p38 PMK-1 innate immune pathway in the intestine during pathogen infection.

TIR multimerization and phase transition superactivates its intrinsic NAD⁺ glycohydrolase activity.

To further characterize the mechanism of TIR-1/SARM1 activation, we recombinantly expressed and purified the TIR domain of the TIR-1 protein (called TIR) from *E. coli* and evaluated its NADase activity *in vitro* using an etheno-NAD⁺ (ε-NAD) activity assay, in which hydrolysis of the nicotinamide moiety of ε-NAD leads to an increase in fluorescence. Interestingly, purified TIR only shows very modest NADase activity even at high protein

concentrations ($>15\ \mu\text{M}$) (Fig. 2A). Notably, the NADase activity of TIR increased parabolically with increasing TIR concentrations rather than linearly, suggesting that multimerization of TIR-1 potentiates its NADase activity (Fig. 2A).

Given that high concentrations of TIR are required to observe NADase activity, we hypothesized that molecular crowding might activate the enzyme. Therefore, we assessed the effect of several macro- and microviscogens on TIR activity. Macroviscogens reduce the free volume available for protein movement and thus promote aggregation of protein complexes that are capable of self-association (42, 43). Importantly, macroviscogens have minimal impact on the rate of diffusion of small molecules. By contrast, microviscogens, which are much smaller than most enzymes, affect the diffusion of substrates in solution and, thus, the frequency at which enzymes encounter their substrate (43). Interestingly, macroviscogens [polyethylene glycol (PEG) 3350 and PEG 8000], but not microviscogens (sucrose or glycerol), dramatically increased the NADase activity of TIR (Fig. 2B). These effects were most pronounced with higher molecular weight PEGs, as treatment with smaller molecular weight PEGs (e.g., PEG 1500 and PEG 400) did not increase the enzymatic activity of TIR (Fig. 2C). Specifically, PEGs 3350 and 8000 increase TIR activity in a concentration-dependent manner (Fig. 2C). Crowding agents also increase the activity of the TIR domain of human SARM1, as well as plant TIR domains (14, 25), suggesting that the mechanism of TIR regulation is strongly conserved.

Treatment with 25% PEG 3350 led to a roughly linear association between TIR concentration and NADase activity and markedly enhanced TIR activity at each enzyme concentration (Fig. 2 – figure supplement 1A). Consequently, lower amounts of enzyme ($2.5\ \mu\text{M}$ TIR) can be used to obtain robust kinetic data. Using these conditions, we determined the steady-state kinetic parameters (k_{cat} , K_{M} , and $k_{\text{cat}}/K_{\text{M}}$) with $2.5\ \mu\text{M}$ TIR in the presence of increasing concentrations of PEG 3350 (Fig. 2D). The K_{M} of TIR increases and then decreases to level off at $\sim 500\ \mu\text{M}$ of ϵ -NAD with increasing concentration of PEG 3350 (Fig. 2E). On the

other hand, k_{cat} increases nearly linearly with increasing concentrations of PEG 3350 (Fig. 2F). In addition, the catalytic efficiency ($k_{\text{cat}}/K_{\text{m}}$) followed the same trend as k_{cat} , indicating that increased TIR activity is due to increased substrate turnover by the enzyme and not tighter substrate binding (Fig. 2G).

We found that the NAD hydrolase activity of TIR is also activated by the precipitant sodium citrate, providing an orthologous method to characterize the enzymatic activity of the TIR domain (Fig. 2 – figure supplements 1A and 1B). Notably, the response to increasing citrate concentration was switch-like, where a concentration of at least 250 mM sodium citrate was needed to observe enzyme activity (Fig. 2 – figure supplements 1B and 1C). By contrast, activation with PEG 3350 was more dose-dependent (Figs. 2C and 2D). Nevertheless, the kinetic parameters obtained in the presence of citrate displayed similar trends to those found with PEG 3350: K_{m} decreased to level off at ~400 μM of $\epsilon\text{-NAD}$ (Fig. 2 – figure supplement 1D), k_{cat} increases with increasing sodium citrate concentration (Fig. 2 – figure supplement 1E), and $k_{\text{cat}}/K_{\text{m}}$ follows the k_{cat} trends (Fig. 2 – figure supplement 1F).

In the cytoplasm, high concentrations of macromolecules (proteins, nucleic acids, lipids, carbohydrates) cause molecular crowding and induce phase transitions of signaling proteins (44). To determine if TIR undergoes a phase transition and whether its NADase activity correlates with the transition, we incubated purified TIR with different concentrations of PEG3350 or citrate, centrifuged the sample, and evaluated TIR NADase activity in the soluble and insoluble fractions (Figs. 2H and Fig. 2 – figure supplement 1G). At low concentrations of both PEG and citrate, TIR protein was present in the supernatant. However, at high concentrations of both PEG and citrate, TIR was principally located in the pelleted (insoluble) fraction, as visualized by Coomassie staining on an SDS-PAGE gel (Figs. 2H and Fig. 2 – figure supplement 1G). Importantly, robust NADase activity was observed in the pelleted fraction and not in the supernatant of samples treated with high concentrations of PEG or citrate (Figs. 2H

and Fig. 2 – figure supplement 1G). Taken together, these data demonstrate that precipitation/aggregation of TIR is required to activate the intrinsic NADase activity of TIR-1/SARM1.

To determine whether TIR-1 multimerization is also required for a phase transition and the NADase activity of TIR, we recombinantly expressed and purified the TIR domain of TIR-1, which contained mutations in residues required for oligomerization (TIR^{G747P} and TIR^{H833A}) and NAD⁺ hydrolysis (TIR^{E788A} and TIR^{E788Q}). Notably, TIR^{G747P} and TIR^{E788Q} mutants showed no apparent activity, and TIR^{E788A} and TIR^{H833A} showed a >1x10⁸-fold decrease in catalytic efficiency (k_{cat}/K_m) compared to TIR^{WT} (Fig. 2I). Similarly, kinetic analysis of TIR oligomerization and catalytic mutants in 500 mM citrate revealed that all the mutants were catalytically dead, each showing no apparent activity (Fig. 2 – figure supplement 1H).

To further characterize the TIR phase transition, we evaluated the precipitation capacity of TIR oligomerization and catalytic mutants in the presence of PEG 3350 and citrate. Consistent with our genetic data, TIR^{G747P}, which contains a mutation that prevents oligomerization of TIR, was unable to precipitate as readily as TIR^{WT} (Fig. 2J). Compared to TIR^{WT}, the TIR^{G747P} mutant in the presence of PEG 3350 demonstrated a 25% decrease in the amount of precipitated protein (Fig. 2J). We observed similar results in the presence of citrate – compared to TIR^{WT}, the TIR^{G747P} mutant demonstrated a 22% decrease in precipitated protein compared to TIR^{WT} (Fig. 2 – figure supplement 1I). Importantly, TIR proteins with two different mutations in the glutamate required for NAD⁺ catalysis, TIR^{E788A} and TIR^{E788Q}, precipitated to a similar extent as TIR^{WT} (Figs. 2J and 2K, and Fig. 2 – figure supplements 1I and 1J) but had minimal NADase activity (Figs. 2I and Fig. 2 – figure supplement 1H). Collectively, these data demonstrate that a phase transition of TIR-1 is required for its NADase activity.

During phase separations, macromolecules partition into distinct biochemical compartments characterized by a higher concentration dense phase and a lower concentration

dilute phase (20, 21, 23). The dense compartment can have either liquid-like properties in liquid-to-liquid phase separations or solid-like properties in liquid-to-solid phase transitions (21, 22, 24, 45). To determine whether TIR undergoes a liquid-to-liquid or a liquid-to-solid phase transition, we assayed the enzyme activity of TIR in the presence of 1,6-hexanediol, an aliphatic alcohol that interferes with hydrophobic interactions prominent in liquid-to-liquid separations. Thus, 1,6-hexanediol disrupts liquid-like compartments, but not solid-like compartments (20, 23, 24). In the presence of either PEG 3350 or citrate, we observed that 1,6-hexanediol decreases the NADase activity of TIR by <2-fold (Fig. 2L). While significant, this modest decrease (the activity of 1,6-hexanediol-treated TIR remains two orders of magnitude higher than the activity of TIR without PEG 3350 or citrate addition) suggests that the NADase activity of TIR is predominantly associated with a solid, rather than a liquid, state or lies on a continuum between a liquid-like and solid-like state (Fig. 2L). Notably, in the absence of PEG 3350 or citrate, the low-level TIR NADase activity can be inhibited by 1,6-hexanediol (Fig. 2L), suggesting that this activity is driven by hydrophobic interactions. Importantly, 1,6-hexanediol does not interfere with TIR precipitation in the presence of PEG or citrate, regardless of whether it is added before or after precipitate formation (Fig. 2 – figure supplements 2A and 2B).

Next, we determined if this liquid-to-solid phase transition of TIR is reversible. The insoluble fraction following treatment of TIR with PEG 3350 or citrate was resuspended in either buffer alone or buffer plus the respective additive (PEG 3350 or citrate). If the phase transition is reversible, resuspension of precipitated TIR in buffer alone should disrupt enzymatic activity. However, if the phase transition is irreversible, activity should be detected when the pellet is resuspended in buffer alone. Notably, we observed some TIR enzymatic activity when the pellet was resuspended in buffer (Fig. 2M). With PEG 3350, the activity was lower than that observed in the precentrifugation control or when the pellet was resuspended in buffer with PEG 3350. By contrast, with citrate, the activity was similar to both control conditions (precentrifugation or when the pellet was resuspended in buffer and citrate). These data indicate that the phase

transition of TIR is partially reversible in PEG 3350 and irreversible in sodium citrate. To confirm these findings, we centrifuged the resuspended samples to examine the fractions visually by SDS-PAGE (Fig. 2 – figure supplement 2C). In the sample initially prepared with PEG 3350 and resuspended in buffer alone, a faint band was present in the supernatant fraction. However, this band was absent in the sample initially prepared with sodium citrate (Fig. 2 – figure supplement 2C). These data confirm that the TIR phase transition is partially reversible in PEG 3350 and irreversible in sodium citrate, at least under these conditions.

Next, we evaluated the effect of pH on TIR precipitation and NADase activity. There was virtually no increase in TIR precipitation in the absence of PEG. However, in the presence of 25% PEG, TIR precipitation increased with increasing pH (Fig. 2 – figure supplement 2D). Under these same conditions, no activity was apparent below pH 6. K_m remained constant (Fig. 2 – figure supplement 2E), and k_{cat} increased from pH 6.5 to pH 8.5 (Fig. 2 – figure supplement 2F). A corresponding increase in k_{cat}/K_m was responsible for the increase in catalytic efficiency above pH 7 (Fig. 2 – figure supplement 2G). Notably, the increase in k_{cat}/K_m correlated with precipitation (Fig. 2 – figure supplements 2D and 2G), again indicating that a phase transition increases TIR activity.

We performed negative stain electron microscopy to directly visualize TIR aggregation *in vitro* (Fig. 2N). Protein visualization is not possible with PEG because macroviscogens themselves are stained, confounding image analysis. Therefore, we performed this experiment with citrate. In the absence of citrate, we observed borderline fibrillar structures and protein aggregates, but overall, there were no consistent structures (Fig. 2N). However, in the presence of citrate, circular particles emerged (Fig. 2N). These data corroborate our discovery that TIR-1::wrmScarlet aggregates *in vivo* into visible puncta with intestinal epithelial cells (Fig. 1A) in demonstrating that TIR aggregates into higher-order, ring-like structures *in vitro*.

Cholesterol deficiency activates the *C. elegans* p38 immune pathway through the multimerization and NADase activity of TIR-1/SARM1.

C. elegans is a sterol auxotroph and requires dietary sterols for development, lifespan, fecundity, and resistance to pathogen infection (27-33). As such, 5 µg/mL of cholesterol is a standard additive in *C. elegans* laboratory growth medium (46). We found that *C. elegans* grown in the absence of cholesterol supplementation activated GFP-based transcriptional reporters for two putative immune effector genes, T24B8.5p::gfp and *irg-5*p::gfp (Figs. 3A and 3B). T24B8.5 and *irg-5* are expressed in the intestine, induced during infection with multiple pathogens, including *P. aeruginosa*, and controlled by the p38 PMK-1 innate immune pathway (2, 40, 47). qRT-PCR studies confirmed that *C. elegans* in a low cholesterol environment upregulate T24B8.5 and *irg-5*, as well as other innate immune effector genes (*irg-4* and K08D8.4) (Fig. 3C). These data suggest that host defense pathways are activated in the absence of pathogen infection when environmental sterols are scarce.

The nuclear hormone receptor, NHR-8, a homolog of mammalian liver X receptor (LXR) and pregnane X receptor (PXR), is required for the transport, distribution, and metabolism of cholesterol in *C. elegans* (26, 48). Thus, *nhr-8* loss-of-function mutant strains can be used as genetic tools to study conditions of low sterol content. Two previously-characterized *nhr-8* null alleles are *nhr-8(hd117)*, which lacks the first exon (26) and *nhr-8(ok186)*, which is missing most of the ligand-binding domain (48). Notably, the transcription profile of *nhr-8(hd117)* and *nhr-8(ok186)* animals mimics that of wild-type *C. elegans* infected with the bacterial pathogen *P. aeruginosa* (Figs. 3D, Fig. 3 – figure supplement 1A, Supplementary file 1, and Supplementary file 2). The correlation between the transcriptional signatures of either the *nhr-8(hd117)* or the *nhr-8(ok186)* mutant with the genes that are changed in wild-type animals during pathogen infection was significant across all genes ($r = 0.311$ and $r = 0.370$, respectively). Of note, the correlation between these datasets is tighter when comparing only the differentially expressed genes ($r = 0.763$ and $r = 0.849$, respectively) and only genes that are also involved in innate

immunity ($r = 0.677$ and $r = 0.703$, respectively) (Figs. 3D and Fig. 3 – figure supplement 1A). Among the immune effectors that are upregulated in both the *nhr-8(hd117)* and *nhr-8(ok186)* mutants, and in wild type animals infected with *P. aeruginosa*, are T24B8.5, *irg-4*, *irg-5*, and K08D8.4; the same genes whose transcription are also induced by cholesterol deprivation (Figs. 3C, 3D, and Fig. 3 – figure supplement 1A).

To validate these findings, we compared gene expression changes in wild-type *C. elegans* grown in media lacking supplemented cholesterol versus animals grown under standard culture conditions with 5 $\mu\text{g/mL}$ of cholesterol. Consistent with our transcriptome profiling experiments of *nhr-8* loss-of-function mutants, we discovered that innate immune effectors were strongly enriched among genes that were transcriptionally activated during cholesterol deprivation (Fig. 3E). Specifically, the expression of innate immune effectors was significantly correlated in wild-type animals infected with *P. aeruginosa* and in wild-type nematodes starved for cholesterol ($r = 0.610$) (Fig. 3E). Immune effectors that were induced during cholesterol starvation in qRT-PCR studies (*irg-4*, *irg-5*, K08D8.5, and T24B8.5) were again found among these differentially regulated genes, confirming the integrity of our RNA-seq analysis (Fig. 3C). These observations were confirmed in a separate RNA-seq experiment (49). Importantly, a comparison of the transcriptional changes in *nhr-8(hd117)* mutants with the genes regulated by low cholesterol revealed a remarkable correlation across all genes ($r = 0.578$) and differentially expressed genes ($r = 0.836$) (Fig. 3 – figure supplement 1B). Together with previous work characterizing the role of *nhr-8* in *C. elegans* cholesterol metabolism (26), these data support the use of *nhr-8* mutants to study conditions of low sterol content. In summary, cholesterol-starved, wild-type *C. elegans* and two different *nhr-8* loss-of-function mutants induce the transcription of innate immune defenses.

Two different supplementation experiments using the T24B8.5p::*gfp* immune reporter demonstrated that immune effector activation in *nhr-8(hd117)* mutants is due to sterol deficiency in these animals. First, supplementation of exogenous cholesterol at an increased concentration

(80 µg/mL) fully suppressed T24B8.5p::*gfp* activation in the *nhr-8(hd117)* mutant (Fig. 3F). Second, supplementation with the non-ionic detergents Tergitol or Triton X-100, which solubilize hydrophobic, amphipathic compounds, including sterols, suppressed T24B8.5p::*gfp* activation in *nhr-8(hd117)* animals in a manner that was dependent on the presence of added cholesterol in the growth media (Figs. 3G, 3H, and Fig. 3 – figure supplement 1C). Nematode growth media solidified with agarose, rather than agar, contains markedly fewer contaminating sterols (26, 28, 36). Importantly, on agarose, the addition of Tergitol to the growth media also suppressed T24B8.5p::*gfp* activation in the *nhr-8(hd117)* mutant, but only in the presence of 5 µg/mL of cholesterol (Fig. 3H). Notably, this effect was dose-dependent (Fig. 3 – figure supplement 1C). These data establish that solubilization of cholesterol by Tergitol in standard nematode growth media suppresses immune activation in the *nhr-8(hd117)* mutant background. We used qRT-PCR to confirm these findings – Tergitol suppressed activation of T24B8.5, as well as the immune effectors *irg-4*, *irg-5* and K08D8.4 in the *nhr-8(hd117)* mutant (Figs. 3I-L). Of note, activation of immune defenses in *nhr-8(hd117)* animals is specific to cholesterol deprivation in this genetic background, as supplementation with individual unsaturated, mono- and polyunsaturated fatty acids, which are also misregulated in the *nhr-8(hd117)* mutant background (26), failed to suppress activation of T24B8.5p::*gfp* (Fig. 3 – figure supplement 1D). Together, these data confirm that cholesterol deprivation activates immune effector transcription independent of bacterial infection.

It has been previously shown that wild-type *C. elegans* raised on media without supplemented cholesterol are hypersusceptible to killing by *P. aeruginosa*, as are *nhr-8(hd117)* mutants on media with standard cholesterol supplementation (5 µg/mL) (32). Importantly, we found that high doses of cholesterol (80 µg/mL) rescued the enhanced susceptibility of *nhr-8(hd117)* mutants to *P. aeruginosa* infection (Fig. 3M). We confirmed this finding using an orthologous approach. Two detergents (Tergitol or Triton X-100), which solubilize cholesterol in nematode growth media, also restored wild-type pathogen resistance to the *nhr-8(hd117)*

mutant (Fig. 3N), consistent with their ability to modulate the expression of innate immune effectors (Fig. 3G-L). Importantly, we found that the *nhr-8(hd117)* mutant accumulated less *P. aeruginosa* in its intestine during infection than wild-type animals (Fig. 3O). Taken together, these data suggest that low cholesterol in the *nhr-8(hd117)* mutants reduces tolerance to pathogen infection, and that the robust transcriptional induction of immune effectors in this mutant background leads to reduced accumulation of *P. aeruginosa* during infection.

Additional analyses of the transcriptome profiling data revealed that targets of the p38 PMK-1 innate immune pathway were strongly enriched among the genes induced in wild-type animals during cholesterol deprivation (Fig. 4A). Accordingly, the levels of active, phosphorylated PMK-1 were higher in wild-type animals grown on media without supplemented cholesterol than in animals grown under standard culture conditions (Figs. 4B and 4C). Consistent with these data, the p38 PMK-1 pathway is also activated in *nhr-8* loss-of-function mutants. A gene set enrichment analysis of the *nhr-8(hd117)* and *nhr-8(ok186)* transcriptome profiling experiments revealed strong enrichment of p38 PMK-1 pathway targets among the genes upregulated in each *nhr-8* mutant (Figs. 4D and Fig. 4 – figure supplement 1A). In addition, the *nhr-8(hd117)* and *nhr-8(ok186)* mutants had an increased ratio of phosphorylated PMK-1 relative to total PMK-1 compared to wild-type controls (Figs. 4E and 4F). RNAi-mediated knockdown of *tir-1*, the most upstream component of the p38 signaling cassette (10, 11), fully suppressed hyperactivation of T24B8.5p::*gfp* in *nhr-8(hd117)* animals (Fig. 4G). The *tir-1(qd4)* loss-of-function mutation completely suppressed the induction of T24B8.5, *irg-4*, *irg-5*, and K08D8.4 in the *nhr-8(hd117)* background (Figs. 4H-K). The transcription factors ATF-7 and SKN-1 link PMK-1 activity to its transcriptional outputs (50, 51). In *nhr-8(hd117)* animals, knockdown of *atf-7*, but not *skn-1*, abrogated T24B8.5p::*gfp* activation (Figs. 4G and Fig. 4 – figure supplements 1B and 1C). Finally, to further support our observation that cholesterol scarcity induces immune defenses upstream of p38 PMK-1, we used the MAPK phosphatase

385 *vhp-1*, a negative regulator of PMK-1 (52). Solubilization of cholesterol with Tergitol was unable
386 to suppress activation of T24B8.5p::*gfp* induced by knockdown of *vhp-1* (Fig. 4L).

387 The c-JUN N-terminal kinase MAPK homolog *kgb-1*, the insulin signaling pathway
388 forkhead box O family (FOXO) transcription factor *daf-16*, and the G protein-coupled receptor
389 (GPCR) *fshr-1*, each function in parallel to the p38 PMK-1 pathway to regulate immune and
390 stress responses in *C. elegans* (2, 52-54). However, knockdown of each of these genes in *nhr-*
391 *8(hd117)* animals failed to suppress T24B8.5p::*gfp* activation (Fig. 4 – figure supplement 1B),
392 and RNAi-mediated knockdown of *nhr-8* did not induce nuclear localization of DAF-16::GFP
393 (Fig. 4 – figure supplement 1D). Thus, cholesterol scarcity induces *C. elegans* innate immune
394 responses through specific activation of p38 PMK-1 immune pathway signaling.

395 Interestingly, *tir-1(qd4);nhr-8(hd117)* double mutants were more susceptible to *P.*
396 *aeruginosa* infection than *nhr-8(hd117)* mutants (Fig. 4M). These data suggest that the
397 induction of the p38 PMK-1 pathway in the *nhr-8(hd117)* mutant background promotes
398 resistance to *P. aeruginosa* infection. In addition, *tir-1(qd4);nhr-8(hd117)* double mutants were
399 slightly, but significantly and reproducibly, more susceptible than the *tir-1(qd4)* mutant to killing
400 by *P. aeruginosa*. We therefore hypothesize that the inherent susceptibility to pathogen-
401 mediated killing in animals that lack sufficient cholesterol [e.g., the *nhr-8(hd117)* mutant] leads
402 to additive pathogen susceptibility in animals that also lack a functioning p38 PMK-1 host
403 defense pathway [e.g., the *tir-1(qd4)* mutant].

404 To determine if sterol scarcity induces oligomerization and the NAD⁺ glycohydrolase
405 activity of TIR-1 to activate the p38 PMK-1 pathway, we examined TIR-1::wrmScarlet puncta
406 formation in the *nhr-8(hd117)* mutant background (Fig. 5A). Consistent with our studies during
407 *P. aeruginosa* infection (Fig. 1A), *nhr-8(hd117)* mutant animals induced TIR-1::wrmScarlet
408 puncta formation in intestinal epithelial cells (Fig. 5A and 5B). Importantly, TIR-1::wrmScarlet
409 puncta formation in *nhr-8(hd117)* animals was entirely suppressed by solubilizing cholesterol in

the growth media with Tergitol (Fig. 5A and 5B). Additionally, treatment of *nhr-8(hd117)* animals expressing TIR-1::wrmScarlet with *tir-1(RNAi)* inhibited fluorescence and puncta formation (Fig. 5A and 5B).

Importantly, the *C. elegans* *tir-1*^{ΔSAM}, *tir-1*^{G747P} and *tir-1*^{H833A} mutants, which contain specific mutations that block oligomerization of TIR-1, and the *tir-1*^{E788A} strain that carries a mutation in the catalytic glutamine required for the NADase activity, each prevented activation of the p38 PMK-1-dependent immune reporter T24B8.5p::gfp in *nhr-8(RNAi)* animals (Fig. 5C) and during cholesterol deprivation (Fig. 5D). Using qRT-PCR, we confirmed that these mutations in *tir-1* abrogated the induction of the T24B8.5 (Fig. 5E) and *irg-4* (Fig. 5F) immune effectors in *nhr-8(RNAi)* animals. We also found that these *tir-1* mutants phenocopied the effects of the p38 PMK-1 pathway mutants [*tir-1(qd4)*, *nys-1(ag3)* and *pmk-1(km25)*] on the basal expression of these immune effector genes (Figs. 5E and 5F).

It is possible that the organization of TIR-1::wrmScarlet into visible puncta in *nhr-8* mutants is secondary to non-specific protein aggregation; however, the *in vitro* and *in vivo* data presented in this manuscript, when considered together, suggest that this is not the case. Organized multimerization of TIR-1 is a prerequisite for the NADase activity of the protein complex *in vitro* (Fig. 2, Fig. 2 – figure supplement 1). Accordingly, the mutations that specifically abrogate TIR-1 multimerization *in vitro* (Figs. 2J, Fig. 2 – figure supplement 1I), also block p38 PMK-1 pathway activation (Figs. 1D-F) and prevented immune effector induction in response to cholesterol deprivation *in vivo* (Figs. 5C-F). Furthermore, Tergitol, which solubilizes cholesterol and fully suppresses p38 PMK-1 immune activation in *nhr-8* mutants (Fig. 3G-3N), also suppresses TIR-1::wrmScarlet puncta formation (Fig. 5A and 5B). Finally and perhaps most importantly, *P. aeruginosa* infection, a separate physiological stress, also induces TIR-1::wrmScarlet puncta formation to activate the p38 PMK-1 pathway (Fig. 1).

In summary, the above data demonstrate for the first time that physiological stresses, both pathogen and non-pathogen, induce TIR-1 multimerization into puncta within intestinal epithelial cells, which then activates the p38 PMK-1 innate immune pathway through the intrinsic NADase activity of the TIR-1 protein complex.

Sterol scarcity primes p38 PMK-1 immune defenses.

Since *C. elegans* requires cholesterol to survive bacterial infection and must obtain this essential metabolite from its diet, we hypothesized that, when environmental sterols are limited, activation of the p38 PMK-1 pathway represents an evolutionary adaptation that primes immune effector expression to anticipate challenges from bacterial pathogens. To test this hypothesis, we examined the expression of innate immune effector genes during bacterial infection in the presence and absence of cholesterol supplementation. Interestingly, the induction of *irg-4p::gfp* (Fig. 6A), *irg-5p::gfp* (Fig. 6B) and T24B8.5p::gfp (Fig. 6C) during *P. aeruginosa* infection was enhanced when nematodes were infected on media that did not contain supplemented cholesterol. Consistent with these data, *P. aeruginosa* infection also led to increased activation of *irg-4p::gfp* (Fig. 6D) and *irg-5p::gfp* (Fig. 6E) when *nhr-8* was depleted by RNAi.

To provide further support for this hypothesis, we analyzed the expression pattern of p38 PMK-1-dependent transcripts in *nhr-8(hd117)* mutant animals during *P. aeruginosa* infection. Of the 472 genes that were induced in wild-type animals during *P. aeruginosa* infection, 184 were also differentially regulated (either induced or repressed) in *nhr-8(hd117)* animals that were infected with *P. aeruginosa*. To perform this analysis in an unbiased manner, we scaled the expression level in each condition for each of these 184 genes by calculating a row z-score and performed hierarchical clustering (Fig. 6F). We observed that these 184 genes group into two clusters: Cluster I had 139 genes and Cluster II contained 45 genes (Supplementary file 5). Cluster I was comprised mostly of genes whose expression in the absence of infection was higher in *nhr-8(hd117)* mutants than wild-type animals (129 of 139 genes). In addition, the

majority of Cluster I genes were more strongly induced during *P. aeruginosa* infection in *nhr-8(hd117)* animals than wild-type animals. Cluster II, on the other hand, contained genes whose induction on *P. aeruginosa* were dependent on *nhr-8*. Importantly, p38 PMK-1-dependent genes were strongly enriched among Cluster I, but not Cluster II, genes (Fig. 6G). Thirty-three of the 139 genes in Cluster I are known targets of the p38 PMK-1 immune pathway (24.17-fold enriched, hypergeometric p-value = 7.68×10^{-37}), a group that includes the immune effectors T24B8.5 (Fig. 6H), *irg-4* (Fig. 6I), *irg-5* (Fig. 6J) and K08D8.4 (Fig. 6K). By contrast, only three genes in Cluster II are p38 PMK-1 dependent transcripts (6.95-fold enriched, hypergeometric p-value = 0.01) (Figs. 6F and 6G).

These data demonstrate that sterol scarcity primes the induction of innate immune effectors by activating the p38 PMK-1 immune pathway. Subsequent challenge by *P. aeruginosa* further drives immune activation in a manner that leads to reduced pathogen accumulation in the intestine (Fig. 3O).

DISCUSSION

Here, we report two conceptual advances. First, we show that a phase transition of *C. elegans* TIR-1, an NADase homologous to mammalian SARM1, underlies p38 PMK-1 immune pathway activation in the *C. elegans* intestine (Fig. 6L). Importantly, we demonstrate that physiologic stresses, both pathogen and non-pathogen, induce multimerization of TIR-1/SARM1 into visible puncta within intestinal epithelial cells. *In vitro* biochemical studies of purified protein and *C. elegans* genetic analysis revealed that multimerization and a phase transition of TIR-1/SARM1 engages its NADase activity to activate the p38 PMK-1 innate immune pathway and provide protection during bacterial infection.

Second, we show that cholesterol deficiency, as recapitulated in an *nhr-8* loss-of-function mutant, causes TIR-1/SARM1 to oligomerize into puncta in intestinal epithelial cells and activate the p38 PMK-1 immune pathway through its intrinsic NADase activity. *C. elegans* lacks the ability to synthesize cholesterol *de novo* and must acquire dietary sterols to support multiple aspects of organismal physiology (27-33). We found that priming of innate immune defenses during conditions of low cholesterol availability augments immune effector induction and leads to decreased accumulation of pathogen in the intestine during a subsequent bacterial infection. We therefore propose that immune activation in this manner represents a new adaptive response that allows a metazoan host to anticipate environmental threats during cholesterol deprivation, a time of relative susceptibility to infection.

Loring et al. demonstrated that human SARM1 aggregates and undergoes a phase transition to potentiate its intrinsic NAD⁺ glycohydrolase activity (25). These authors studied SARM1 in the context of neuronal degeneration as it was previously demonstrated that loss of mammalian SARM1 protects against axonal degeneration following neuronal injury (55-57). Treatment with non-physiologic concentrations of citrate, a molecule that induces protein precipitation, led to puncta formation of *C. elegans* TIR-1 in neurons, which was correlated with enhanced axonal degeneration (25). Moreover, previous studies showed that human SARM1

forms oligomers (58, 59) and that dimerization, at least, is required for TIR domain activity (15, 41, 60). Thus, the demonstration here that *C. elegans* TIR-1/SARM1 aggregates *in vivo* in response to physiological stresses provides an important characterization of the mechanism inferred by Loring et al. and suggests that oligomerization favors the phase transition of TIR-1/SARM1 such that higher-order structures are formed. Of note, the enzyme kinetics of TIR-1 are strikingly similar to mammalian SARM1 – the activity of both proteins is exquisitely dependent on precipitation. Thus, together, these studies demonstrate that a phase transition of TIR-1/SARM1 as a prerequisite for its NAD⁺ glycohydrolase activity is conserved across millions of years of evolution, occurs in multiple cell types, and is essential for diverse physiological processes, including intestinal immune regulation and axonal degeneration.

Currently, it is unknown how low cholesterol leads to the oligomerization and phase transition of *C. elegans* TIR-1/SARM1 and further studies are needed to characterize this mechanism. Cholesterol could be sensed to trigger this response, or low cholesterol could change the biophysical properties of the cell in a manner that favors oligomerization of TIR-1.

We demonstrate that cholesterol supplementation can fully rescue the enhanced susceptibility to pathogen-mediated killing in *nhr-8* loss-of-function mutants (Fig. 3M and 3N). These data suggest that cholesterol is required for pathogen tolerance in *C. elegans*; however, the mechanism behind this observation is unknown. The p38 PMK-1 pathway provides protection during pathogen infection in the *nhr-8* mutant background (Fig. 4M), suggesting that the enhanced susceptibility to pathogen-mediated killing in the *nhr-8* mutant is not secondary to aberrant activation of the p38 PMK-1 pathway. Cholesterol-deficient animals may therefore have general reductions in organismal fitness that cause vulnerability to pathogen infection and a reduction in lifespan.

The robust activation of the p38 PMK-1 pathway and the reduced pathogen burden in *nhr-8* mutants suggests that immune activation in this manner promotes pathogen resistance, which we propose is part of a mechanism to prime protective immune activation. It is also

possible that activation of the p38 PMK-1 pathway during cholesterol deficiency could engage another protective host response that is unrelated to pathogen defense. We do not favor this hypothesis, however, considering the observed reduction in the pathogen burden of the *nhr-8* mutants (Fig. 3O).

We previously demonstrated that a *C. elegans* nuclear hormone receptor, NHR-86, a member of a family of ligand-gated transcription factors, surveys the chemical environment to activate the expression of immune effectors (61). Interestingly, NHR-86 targets immune effectors whose basal regulation requires the p38 PMK-1 immune pathway. However, NHR-86 functions independently of PMK-1 and modulates the transcription of these infection response genes directly. NHR-86 is a nematode homolog of the mammalian nuclear hormone receptor hepatocyte nuclear factor 4 (HNF4), a family of NHRs that expanded dramatically in *C. elegans* (259 HNF4 homologs are encoded in the *C. elegans* genome) (62, 63). One potentially unifying hypothesis is that HNF4 homologs detect pathogen- or host-derived ligands that are associated with infection and activate pathogen-specific immune defenses. In this model, the p38 PMK-1 pathway functions as a rheostat that receives inputs from signals associated with potentially dangerous environmental conditions to prime host immune effector genes. Indeed, inputs from chemosensory neurons, bacterial density, tissue damage and nucleotide metabolism also regulate the tonic level of p38 PMK-1 pathway activity (11, 64-72), suggesting that p38 PMK-1 phosphorylation is adjusted to anticipate dangerous threats during periods of vulnerability. We hypothesize that mechanisms in *C. elegans* that detect specific pathogens can further augment immune effector induction.

ACKNOWLEDGEMENTS AND FUNDING SOURCES

The authors thank Alexandra Byrne, Victoria Czech, Lauren O'Connor, and Heather Loring for helpful discussions. The authors are also grateful to Melanie Trombly and Merin MacDonald for critical reading of the manuscript. This research was supported by R01 AI130289 (to R.P.W.), R01 AI159159 (to R.P.W.), R21 AI163430 (to R.P.W.), an Innovator Award from the Kenneth Rainin Foundation (to R.P.W.), the Dan and Diane Riccio Fund for Neuroscience (to R.P.W. and P.R.T.), F30 AI150127 (to N.D.P.), T32 AI132152 (to N.D.P. and J.D.I.), T32 GM107000 (to N.D.P.), F31 NS122423 (to J.D.I.), and R35 GM118112 (to P.R.T.). Some strains were provided by the *Caenorhabditis* Genetics Center, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440).

MATERIALS AND METHODS

C. elegans and bacterial strains. The previously published *C. elegans* strains used in this study were: N2 Bristol (46), KU25 *pmk-1(km25)* (73), AU3 *nsy-1(ag3)* (1), ZD101 *tir-1(qd4)* (40), AA968 *nhr-8(hd117)* (26), AE501 *nhr-8(ok186)* (48), AU78 *agls219* [T24B8.5p::*gfp::unc-54*-3'UTR; *ttx-3p::gfp::unc-54*-3'UTR] (40), AU306 *agls44* [*irg-4p::gfp::unc-54*-3'UTR; *myo-2p::mCherry*] (74), AY101 *acls101* [pDB09.1(*irg-5p::gfp*); pRF4(*rol-6(su1006)*)] (47), TJ356 *zls356* [*daf-16p::daf-16a/b::gfp* + pRF4(*rol-6(su1006)*)] (75). The strains developed in this study were: RPW278 *nhr-8(hd117);agls219*, RPW317 *tir-1(qd4);nhr-8(hd117)*, RPW339 *tir-1(ums47[E788A]);agls219*, RPW369 *tir-1(ums54[ΔSAM]);agls219*, RPW374 *tir-1(ums55[G747P]);agls219*, RPW381 *tir-1(ums56[H833A]);agls219*, RPW386 *tir-1(ums57[tir-1::3xFLAG]);agls219*, RPW387 *tir-1(ums58[tir-1[E788A]::3xFLAG]);agls219*, RPW388 *tir-1(ums59[tir-1[ΔSAM]::3xFLAG]);agls219*, RPW 389 *tir-1(ums60[tir-1[G747P]::3xFLAG]);agls219*, RPW403 *tir-1(ums63[tir-1::wrmScarlet])*, RPW404 *nhr-8(hd117);tir-1(ums63[tir-1::wrmScarlet])*. Bacteria used in this study are *Escherichia coli* OP50, *E. coli* DH5α, *E. coli* HT115(DE3), and *Pseudomonas aeruginosa* strain PA14 (76).

C. elegans growth conditions and lipid supplementation. *C. elegans* strains were maintained on standard nematode growth medium (NGM) plates [0.25% bacto peptone, 0.3% sodium chloride, 1.7% agar (Fisher), 5 µg/mL cholesterol (Sigma-Aldrich, BioReagent grade), 25 mM potassium phosphate pH 6.0, 1 mM magnesium sulfate, 1 mM calcium chloride] with *E. coli* OP50 as a food source, as described (46). For low cholesterol medium (0 µg/mL cholesterol), NGM was prepared without cholesterol supplementation, while 0.1% ethanol was added to maintain an equivalent ethanol concentration. For high cholesterol medium, cholesterol was dissolved in ethanol at 20 mg/mL and added to NGM at a final concentration of 80 µg/mL immediately prior to pouring plates. For all assays with high cholesterol medium, NGM containing 0.4% ethanol and 5 µg/mL cholesterol were used as control plates. Cholesterol

solubilization assays were performed by supplementing NGM containing 5 µg/mL cholesterol with either 0.1% Tergitol (Sigma-Aldrich) or 0.1% Triton X-100 (Sigma-Aldrich). For assays using media solidified with agarose, NGM plates were prepared with 1.7% Ultrapure agarose (ThermoFisher Scientific) in place of agar. All fatty acids were purchased from Nu-Check-Prep Inc., and supplementation performed as previously described with modification (77, 78). Fatty acids were dissolved in 50% ethanol and added at a final concentration of 1 mM to NGM agarose containing 0 µg/mL cholesterol and 0.1% Tergitol immediately prior to plate pouring. Prior to all assays, plates supplemented with lipids and control plates were seeded with *E. coli* OP50 and grown for 24 hours at room temperature. Assays were performed by picking 10-20 gravid adult animals to either lipid-supplemented or matched control plates. Animals were maintained on the plates for 14 hours at 20°C, after which they were removed. Eggs laid on the plate were allowed to hatch and develop to the L4 stage at 20°C. For low cholesterol assays, animals were grown for two generations on NGM containing 0 µg/mL cholesterol.

C. elegans strain construction. CRISPR/Cas9 was used to generate *tir-1* mutants in both wild-type and TIR-1::3xFLAG backgrounds, as described (79, 80). All CRISPR/Cas9 reagents were purchased from Integrated DNA Technologies. Target guide sequences were selected using the CHOPCHOP web tool (81). ssODN and dsDNA repair templates contained indicated edits, deletions or insertions with 35 bp flanking homology arms. crRNA guide and ssODN sequences are listed in Supplementary file 6. For wrmScarlet dsDNA repair template, wrmScarlet was PCR amplified with 35 bp flanking homology arms. PCR was gel purified, diluted to 100 ng/µL, melted and reannealed using a thermal cycler (95 °C – 2 minutes; 85 °C – 10 seconds, 75 °C – 10 seconds, 65 °C – 10 seconds, 55 °C – 10 seconds, 45 °C – 10 seconds, 35 °C – 10 seconds, 25 °C – 10 seconds, 4 °C – hold. Ramp down 1 °C per second), and used immediately for injection. A mixture of 0.25 µg/µL Cas9, 0.1 µg/µL tracrRNA and 0.056 µg/µL crRNA were incubated for 15 minutes at 37°C. 0.11 µg/µL ssODN or 25 ng/µL dsDNA and 40

ng/μL pRF4(*rol-6(su1006)*) plasmid were added to the mixture, centrifuged and microinjected into young adult animals carrying the *agls219* transgene, *tir-1(ums57[tir-1::3xFLAG]);agls219*, or N2. The F1 progeny were screened for Rol phenotypes 3-4 days after injection and then for indicated edits using PCR and Sanger sequencing. Primer sequences used for genotyping are listed in Supplementary file 6.

Feeding RNAi. Knockdown of target genes was performed by feeding *C. elegans* *E. coli* HT115 expressing dsRNA targeting the gene of interest, as previously described with modification (82-84). In brief, HT115 bacteria expressing dsRNA targeting genes of interest were grown in Lysogeny broth (LB) Lennox medium containing 50 μg/mL ampicillin and 15 μg/mL tetracycline overnight with shaking (250 rpm) at 37°C. Overnight cultures were seeded onto NGM containing 5 mM IPTG and 50 μg/mL carbenicillin and incubated at 37°C for 16 hours, after which synchronized L1 animals were transferred to bacterial lawns and allowed to grow until the L4 stage.

***C. elegans* Bacterial Infection and Colonization Assays.** “Slow killing” *P. aeruginosa* infection experiments were performed as previously described (85, 86). Wild-type is either N2 or *agls219*. In brief, a single colony of *P. aeruginosa* PA14 was inoculated into 3-mL of LB medium and grown with shaking (250 rpm) at 37°C for 14 hours. 10-μL of overnight culture was spread onto 35-mm petri dishes containing 4-mL slow killing agar (0.35% peptone, 0.3% sodium chloride, 1.7% agar, 5 μg/mL cholesterol, 25 mM potassium phosphate pH 6.0, 1 mM magnesium sulfate, 1 mM calcium chloride). Plates were incubated for 24 hours at 37°C and for approximately 24 hours at 25°C. Immediately prior to starting the assay, 0.1 mg/mL 5-fluorodeoxyuridine (FUDR) was added on top of the agar to prevent progeny from hatching. Animals used in all assays were grown at 20°C with specified growth conditions. For assays involving high cholesterol or nonionic detergents, slow-killing agar plates were prepared with

either 80 µg/mL cholesterol (Sigma-Aldrich), 0.1% Tergitol (Sigma-Aldrich), or 0.1% Triton X-100 (Sigma-Aldrich). For experiments using plates containing 80 µg/mL cholesterol, matched control plates containing the equivalent ethanol concentration (0.4%) and 5 µg/mL cholesterol were prepared. All pathogenesis and lifespan assays are representative of three biological replicates. Sample sizes, mean lifespan, and p values for all trials are shown in Supplementary file 4.

Colony-forming units of *P. aeruginosa* were quantified in the intestine of *C. elegans* as previously described with modifications (86, 87). Briefly, *C. elegans* animals were exposed to lawns of *P. aeruginosa*, which were prepared as previously described, for 24 hours. Animals were then picked to NGM plates lacking bacteria and incubated for 10 minutes to remove external *P. aeruginosa*. Animals were then transferred to a second NGM plate, after which 10-11 animals per replicate were collected, washed with M9 buffer containing 25 mM tetramisole (Sigma-Aldrich) and 0.01% Triton X-100 (Sigma-Aldrich), and ground with 1.0 mm silicon carbide beads (BioSpec Products). *P. aeruginosa* CFUs were quantified from serial dilutions of the lysate grown on LB agar.

Gene expression analysis and bioinformatics. 2,000 synchronized L1 stage *C. elegans* of the indicated genotypes were grown to the L4 stage and harvested by washing with M9. For expression analysis of *C. elegans* genes during *P. aeruginosa* infection, animals at the L4 stage were transferred by washing to plates containing *E. coli* OP50 or *P. aeruginosa* PA14 lawns. Animals were exposed for four hours and subsequently harvested by washing with M9. RNA was isolated using TriReagent (Sigma-Aldrich), column purified (Qiagen), and analyzed by 100 bp paired-end mRNA-sequencing using the BGISEQ-500 platform (BGIAmericasCorp) with >20 million reads per sample. Raw fastq reads were evaluated by FastQC (version 0.11.5), clean reads were aligned to the *C. elegans* reference genome (WBcel235) and quantified using Kallisto (version 0.45.0) (88). Differentially expressed genes were identified using Sleuth

(version 0.30.0) (89). Pearson correlation statistical analysis was performed using Prism 9.0. Innate immune genes were identified using DAVID Bioinformatics database biological process gene ontology (GO) term innate immune response (90). Heatmaps of differentially expressed genes were generated using pheatmap (version 1.0.12). Gene set enrichment analysis of RNA-seq was performed using GSEA (version 4.1.0) (91) with a custom gene set database (Supplementary file 7) containing p38 PMK-1 dependent genes generated by analyzing previously published RNA-seq of uninfected *pmk-1(km25)* animals (92) with the RNA-seq data analysis pipeline described above. Differential gene expression was defined as a fold change (FC) versus wild-type greater than 2 and q less than 0.01.

For the qRT-PCR studies, RNA was reverse transcribed to cDNA using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.), amplified and detected using Syber Green (Bio-Rad Laboratories, Inc.) and a CFX384 machine (Bio-Rad Laboratories, Inc.). The sequences of primers that were designed for this study are presented in Supplementary file 6. Other primers were previously published (2, 93-95). All values were normalized against the geometric mean of the control genes *snb-1* and *act-3*. Fold change was calculated using the Pfaffl method (96).

Immunoblot analyses. Protein lysates from 2,000 *C. elegans* grown to the L4 larval stage on *E. coli* OP50 on NGM agar were prepared as previously described with modification (61, 97). Harvested animals were washed twice with M9 buffer and resuspended in RIPA Buffer (Cell Signaling Technology, Inc.) containing 1x Halt Protease and Phosphatase inhibitor (ThermoFisher Scientific). Samples were lysed using a teflon homogenizer, centrifuged, and protein was quantified from the supernatant of each sample using the DC protein assay (Bio-Rad Laboratories, Inc.). NuPAGE™ LDS sample buffer (ThermoFisher Scientific) was added to a concentration of 1X, and 12.5–30 µg of total protein from each sample was resolved on NuPAGE™ 4-12% BisTris (Phospho-PMK-1 and Total-PMK-1) or NuPAGE™ 3-8% TrisAcetate

(TIR-1::3xFLAG) gels (ThermoFisher Scientific), transferred to nitrocellulose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc.), blocked with 5% milk powder in TBST and probed with a 1:1000 dilution of an antibody that recognizes the doubly-phosphorylated TGY motif of PMK-1 (Cell Signaling Technology, #9211), a previously characterized total PMK-1 antibody (61), a monoclonal mouse anti-FLAG antibody (Sigma-Aldrich, M2), or a monoclonal mouse anti-alpha-tubulin antibody (Sigma-Aldrich, Clone B-5-1-2). Horseradish peroxidase (HRP)-conjugated anti-rabbit (Cell Signaling Technology, #7074) and anti-mouse IgG secondary antibodies (Abcam, #ab6789) were diluted 1:10,000 and used to detect the primary antibodies following the addition of ECL reagents (Thermo Fisher Scientific, Inc.), which were visualized using a BioRad ChemiDoc MP Imaging System. The band intensities were quantified using Fiji/ImageJ, and the ratio of active phosphorylated PMK-1 to total PMK-1 was calculated.

TIR-1::wrmScarlet puncta visualization. For TIR-1::wrmScarlet puncta visualization, all TIR-1::wrmScarlet expressing animals were depleted of autofluorescent gut granules by exposure to *glo-3(RNAi)* from the L1 stage prior to all experiments. *P. aeruginosa* was prepared as described for bacterial infection and colonization assays. L4 animals expressing TIR-1::wrmScarlet were transferred to either OP50 or *P. aeruginosa* containing plates for 24 hours. For imaging, animals were transferred to 2% agarose pads, paralyzed with 300 mM sodium azide, and imaged with a 63x oil immersion lens. For Tergitol experiments, animals were grown on RNAi plates containing 0.1% Tergitol and the respective RNAi strains and imaged at the L4 stage.

Microscopy. Nematodes were mounted onto agar pads, paralyzed with 10 mM levamisole (Sigma) or 300 mM sodium azide and photographed using a Zeiss AXIO Imager Z2 microscope with a Zeiss Axiocam 506mono camera and Zen 2.3 (Zeiss) software.

712

713 **Microscopy image analysis.** Image processing and analysis were performed using Fiji image
714 analysis software. In each panel, the exposure time and processing for all images were
715 identical. To quantify T24B8.5p::gfp fluorescence intensity, the DIC channel was used to identify
716 and select the intestine of each animal using the Freehand Tool. The integrated density, which
717 is the product of the area and mean gray value, was then calculated for the green channel of
718 each selected region using the Measurement function. To quantify TIR-1::wrmScarlet puncta,
719 the last posterior pair of intestinal epithelial cells were identified in the DIC channel and selected
720 using the Freehand Tool. We then filtered the red and green channel images using Gaussian
721 Smoothing (sigma radius=1). The Find Maxima tool was then used to identify puncta in the red
722 channel within the selected area. The Find Maxima settings used for the analysis of *P.*
723 *aeruginosa* puncta were prominence: 5, strict: no, exclude edge maxima: no. The settings for
724 the *nhr-8(hd117)* and Tergitol experiments were prominence: 15, strict: no, exclude edge
725 maxima: no. We then overlaid the location of the red channel puncta in the green channel and
726 determined if there was an autofluorescent puncta in this exact location. TIR-1::wrmScarlet
727 puncta were those that were present in the red, but not the green, channel. Importantly, we only
728 reported puncta that were positively identified by the image analysis software.

729

730 **TIR-1 TIR domain expression and purification.** The recombinant *C. elegans* TIR-1 TIR
731 domain (TIR) was expressed in bacteria as previously described (98). Briefly, the TIR domain
732 cloned into the pET-30a(+) vector was transformed into chemically competent *E. coli*
733 BL21(DE3) cells and maintained as a glycerol stock at -80°C. An inoculation loop was used to
734 transfer the transformed bacteria into 5 mL of LB media with 50 µg/mL (final concentration) of
735 kanamycin, and the culture was grown overnight at 37°C while rotating. The next day, the
736 cultures were diluted 1:400 in LB media with 50 µg/mL (final concentration) of kanamycin and
737 grown at 37°C while shaking at 215 rpm until an OD₆₀₀ of 0.7-0.8 was reached. After cooling, 50

738 μ M IPTG (final concentration) was added to the culture to induce protein expression. The
739 incubator temperature was decreased to 16°C, and cells were incubated for an additional 16-18
740 h. Bacterial cells were collected by centrifugation at 3,000 x g for 15 min at 4°C, flash frozen in
741 liquid nitrogen, and stored at -80°C until purification.

742 For purification, bacterial pellets were thawed on ice and then resuspended in Lysis
743 Buffer (50 mM Tris•HCl pH 7.0, 300 mM NaCl, 10% (w/v) glycerol, 0.001% Tween 20) with
744 Pierce[™] EDTA-free protease inhibitor mini tablets (ThermoFisher Scientific). The resuspension
745 was incubated with 100 μ g/mL lysozyme for 10 min at 4°C and sonicated with a Fisher Scientific
746 Sonic Dismembrator sonicator (FB-705) in 50-mL batches at an amplitude of 30 for 20 s, pulsing
747 for 1 sec on and 1 sec off, followed by a delay period of 20 s for a series of 12 cycles. Crude
748 lysate was clarified at 21,000 x g for 25 min at 4°C, at which point the supernatant was applied
749 to pre-equilibrated Strep-Tactin XT Superflow high-capacity resin (IBA Lifesciences) and
750 allowed to enter the column by gravity flow; the Strep-Tactin resin had been equilibrated in
751 Strep Wash Buffer (50 mM Tris•HCl pH 7.0, 300 mM NaCl). The column was washed with 30
752 column volumes of Strep Wash Buffer, and the protein was eluted with 25 column volumes of
753 Strep Elution Buffer (Strep Wash Buffer with 50 mM biotin). The protein eluted from the Strep-
754 Tactin column was then applied to pre-equilibrated TALON Metal Affinity Resin (Takara) and
755 allowed to enter the column by gravity flow; the TALON resin was equilibrated in His Wash 1 (50
756 mM Tris•HCl pH 7.0, 150 mM NaCl, 5 mM imidazole). A series of 15 column volume washes
757 were applied (His Wash 1; His Wash 2: 50 mM Tris•HCl pH 7.0, 150 NaCl, 10 mM imidazole),
758 and the protein was eluted in 20 column volumes of His Elution Buffer (50 mM Tris•HCl pH 7.0,
759 150 mM NaCl, 150 mM imidazole). The eluted protein was dialyzed overnight in Dialysis Buffer
760 (50 mM Tris•HCl, pH 7.0, 150 mM NaCl). The next day, the protein was concentrated using a
761 10,000 NMWL Amicon Ultra-15 Centrifugal Filter Unit at 4°C, and the protein concentration was
762 determined by the Bradford assay. TIR was flash frozen in liquid nitrogen and stored at -80°C in
763 25- μ L aliquots.

764

765 **Fluorescent NADase Assay.** Nicotinamide 1,N⁶-ethenoadenine dinucleotide (ϵ -NAD, Sigma-
766 Aldrich) is a fluorescent analog of NAD⁺ and was utilized in kinetic assays as a TIR-1 substrate.
767 TIR-1 cleaves the nicotinamide moiety from ϵ -NAD to release nicotinamide and etheno-ADPR
768 (ϵ -ADPR), which fluoresces ($\lambda_{\text{ex}} = 330$ nm, $\lambda_{\text{em}} = 405$ nm). Enzymatic activity was assayed in
769 Assay Buffer (50 mM Tris pH 8.0, 150 mM NaCl; final concentration) using Corning® 96-well
770 Half Area Black Flat Bottom Polystyrene NBS™ Microplates for a final reaction volume of 60- μ L,
771 or Corning® 384-well Low Volume Black Round Bottom Polystyrene NBS™ Microplates for a
772 final volume of 20- μ L; reactions were initiated by the addition of ϵ -NAD. ϵ -ADPR fluorescence
773 intensity readings were taken in real time every 15 sec for 15-30 min using Wallac EnVision
774 Manager Software and a PerkinElmer EnVision 2104 Multilabel Reader. Fluorescence intensity
775 readings ($\lambda_{\text{ex}} = 330$ nm, $\lambda_{\text{em}} = 405$ nm) were converted to [ϵ -ADPR] with an ϵ -ADPR standard
776 curve, which was produced by incubating fixed concentrations (0-400 μ M) of ϵ -NAD with excess
777 ADP-ribosyl cyclase and plotting the peak fluorescence intensity values against [ϵ -ADPR]. The
778 activity was linear with respect to time under all conditions tested.

779

780 **Effect of crowding agents and sodium citrate on the activity of the TIR domain.** The
781 enzymatic activity of the TIR domain was evaluated using the Fluorescent Assay described
782 above. First, the enzyme concentration dependence was determined. For purified protein, the
783 enzyme (0-32.5 μ M; final concentration) was added to Assay Buffer in duplicate, briefly
784 incubated at room temperature for 10 min, and the reaction was initiated with 1 mM ϵ -NAD.
785 Fluorescence intensity was monitored in real time every 15 sec for 15 min.

786 To evaluate the effect of crowding agents and sodium citrate on TIR activity, stock
787 solutions of the additives were made. 50% (w/v) solutions of PEGs 8000, 3500, 1500, and 400,
788 as well as 60% (w/v) solutions of dextran, sucrose, and glycerol were prepared and filtered.
789 Initially, the concentration dependence of TIR in the presence of PEG 3350 was determined.

TIR (0-15 μ M; final concentration) was added to Assay Buffer with 25% PEG 3350 (final concentration) in duplicate, incubated for 10 min at room temperature, initiated with 1 mM ϵ -NAD, and monitored every 15 sec for 15 min. The concentration dependence of TIR in 25% PEG 3350 was used to establish that 2.5 μ M TIR could be used to enable robust kinetic analyses. Next, the effect of viscosogens on TIR activity was evaluated by adding 2.5 μ M TIR (final concentration) in duplicate to Assay Buffer with or without 25% w/v of the viscosogens (final concentration). Following a brief 10 min incubation period, the reaction was initiated with 1 mM ϵ -NAD and monitored every 15 sec for 20 min. The dose response of 2.5 μ M TIR to the viscosogens (0, 10, 20, and 30% final concentrations) was evaluated in the same manner and monitored every 15 sec for 15 min.

Sodium citrate was prepared as a stock solution of 2 M and filtered. The concentration dependence of TIR in the presence of 500 mM sodium citrate was determined. TIR (0-15 μ M; final concentration) was added to Assay Buffer with 500 mM citrate (final concentration) in duplicate, incubated for 10 min at room temperature, and then the reaction was initiated with 1 mM ϵ -NAD and monitored every 15 sec for 15 min. Additionally, the dose dependence of sodium citrate was determined in duplicate. 2.5 μ M TIR was added to Assay Buffer with (0-1000 mM) sodium citrate and briefly incubated at room temperature for 10 min. The reaction was initiated with 1 mM E-NAD, and fluorescence was monitored every 15 sec for 15 min.

In all cases, the fluorescence intensity was converted to ϵ -ADPR using the ϵ -ADPR standard curve described above. Slopes of the progress curves yielded the velocities of the reactions, which were plotted in GraphPad Prism.

Effect of PEG 3350 and sodium citrate on steady-state kinetics. Steady-state kinetic reactions were carried out in Assay buffer with either PEG 3350 (0-25%; final concentration) or sodium citrate (0-1000 mM; final concentration); a constant concentration of 2.5 μ M TIR was used in these assays. Reaction components were mixed in duplicate and incubated at room

temperature for 10 min before initiating the reaction with ϵ -NAD (0-4000 μ M, final concentration). Fluorescence intensity was monitored every 15 sec for 15 min. Using the ϵ -ADPR standard curve, the fluorescence was converted to [ϵ -ADPR]. The velocity of the reactions was calculated from the slope of the progress curve at each ϵ -NAD concentration and plotted in GraphPad Prism. Kinetic parameters were determined by fitting these velocities to the Michaelis-Menten equation (Eq. 1) at each PEG 3350 or sodium citrate concentration. K_m , k_{cat} , and k_{cat}/K_m values were plotted against PEG 3350 or sodium citrate concentration.

Eq.1
$$v = \frac{V_{max}[S]}{K_m + [S]},$$

Where V_{max} is the maximum velocity, $[S]$ is the substrate concentration, and K_m is the substrate concentration at half the maximum velocity.

The TIR domain precipitates in PEG3350 and sodium citrate. 5 μ M TIR was incubated in Assay Buffer with PEG 3350 (0, 10, 17.5, and 25%; final concentration) or sodium citrate (0, 125, 250, 500, 750, and 1000 mM; final concentration) in duplicate at room temperature for 15 min. The precentrifugation control was removed, and the remainder of the sample was centrifuged at 17,000 $\times g$ at 4 $^{\circ}$ C for 10 min. Following centrifugation, the supernatant was separated from the pellet, and the pellet was resuspended in Assay Buffer with the respective concentration of PEG 3350 or sodium citrate. Samples were diluted 1:2 with gel loading buffer and run on an SDS-PAGE gel. Protein bands were stained by Coomassie and visualized on a BioRad Gel Doc EZ Gel Documentation System with Image LabTM Software. Representative images are shown.

Following resuspension of the pellet, all fractions were analyzed in the Fluorescent Assay. After the samples were aliquoted into the assay plate in duplicate, the enzymatic reaction was initiated with 1 mM ϵ -NAD and monitored every 15 sec for 15 min. Fluorescence intensity was converted to ϵ -ADPR concentration using the ϵ -ADPR standard curve. Slopes of

the progress curves yielded the velocities of the reactions, which were plotted in GraphPad Prism.

Effect of 1,6-hexanediol on TIR domain activity and precipitation. To evaluate the effect of 1,6-hexanediol on TIR activity, the Fluorescent Assay was performed in triplicate in the absence and presence of PEG 3350 or sodium citrate. For pure protein, 35 μ M TIR (final concentration) was incubated in Assay Buffer at room temperature for 10 min with or without 2% 1,6-hexanediol (final concentration). For PEG 3350 or citrate, 2.5 μ M TIR was incubated in Assay Buffer with 25% PEG 3350 or 500 mM sodium citrate (final concentrations) for 10 min at room temperature with or without 2% 1,6-hexanediol. The reactions were initiated with 1 mM ϵ -NAD and monitored every 15 sec for 15 min. Using the ϵ -ADPR standard curve, fluorescence was converted to [ϵ -ADPR], and the reaction velocities (i.e., slopes of the progress curves) were obtained. Velocities were normalized for enzyme concentration, and these normalized velocities were plotted in GraphPad Prism.

To determine whether 1,6-hexanediol can alter TIR precipitation, 1,6-hexanediol was added either before or after TIR precipitation in duplicate. To assess whether 1,6-hexanediol disrupts TIR precipitation, TIR precipitates were formed first by incubating 10 μ M TIR (final concentration) with 25% PEG3350 or 500 mM sodium citrate (final concentration) at room temperature for 15 min. 1,6-hexanediol (0, 1, or 2%; final concentrations) was added to the mixture and incubated at room temperature for an additional 10 min. The precentrifugation control was removed, and the remaining mixture was centrifuged at 21,000 $\times g$ for 10 min at 4°C. Supernatant fractions were removed, and the pellet was resuspended in Assay Buffer with the respective additive and concentration of 1,6-hexanediol. All fractions were run on an SDS-PAGE and stained with Coomassie Blue, and gels were imaged on a BioRad Gel Doc EZ Gel Documentation System with Image LabTM Software. Next, we determined if 1,6-hexanediol could prevent TIR precipitation. 10 μ M TIR was incubated in Assay Buffer with 1,6-hexanediol

(0, 1, or 2%; final concentration) for 15 min at room temperature. 25% PEG 3350 or 500 mM sodium citrate was added to the TIR-buffer-hexanediol mixture and incubated further for 10 min. Controls were removed and the samples were centrifuged at 21,000 x g for 10 min at 4°C. As before, supernatant fractions were removed, and pellet fractions were resuspended in Assay Buffer with respective additives and hexanediol concentrations. Fractions were analyzed by SDS-PAGE/Coomassie staining; representative images are shown.

Phase Transition Reversibility. To evaluate the reversibility of the TIR phase transition, 5 μ M of TIR was mixed with Assay Buffer and 25% PEG 3350 or 500 mM sodium citrate in duplicate (final concentrations). Following a 15 min incubation period at room temperature, precentrifugation controls were removed and the sample remaining was centrifuged at 17,000 x g for 10 min at 4°C. Supernatant fractions were separated from the pellet, which was resuspended in either Assay Buffer alone or Assay Buffer with respective additive. All fractions were analyzed for enzymatic activity in the Fluorescent Assay. Briefly, the precentrifugation, supernatant, and pellet fractions were aliquoted into the assay plates in duplicate and the reaction was initiated with 1 mM ϵ -NAD. Fluorescence was converted to [ϵ -ADPR] concentration with the ϵ -ADPR curve to yield the progress curves. The velocity of the reactions was taken as the slope of the line and the velocities were plotted in GraphPad Prism.

To validate the kinetic data, 10 μ M TIR (final concentration) was incubated in Assay Buffer with either 25% PEG 3350 or 500 mM sodium citrate (final concentration) for 15 min at room temperature; control samples were incubated in Assay Buffer only. Samples were centrifuged at 21,000 x g for 10 min at 4°C, after which the supernatant was separated from the pellet. The pellets from samples initially prepared with additives were resuspended in either Assay Buffer alone or Assay Buffer plus the respective additive; this was not necessary for the sample initially prepared without additive since the protein is primarily located in the supernatant in this case. After removing another control sample (Additive lanes on gel), the resuspended

893 samples were centrifuged again at 21,000 x g for 10 min at 4°C. As before, the supernatant was
894 removed, and the pellet was resuspended in Assay Buffer with the respective additive. All
895 samples were analyzed for protein content on an SDS-PAGE gel and stained with Coomassie
896 Blue.

897
898 **Effect of pH on TIR domain precipitation and kinetics.** To determine the effect of pH on TIR
899 precipitation, the experiments described above were carried out in duplicate at pH values from
900 4.5-9.0. Briefly, 5 µM TIR (final concentration) was mixed with Assay Buffer (50 mM buffer; 150
901 NaCl) with and without 25% PEG 3350 (final concentration); for pH 4.5-5, sodium acetate buffer
902 was used; for pH 5.5-6.5, MES was used; for pH 7-9, Tris was used. The samples were
903 incubated for 15 min at ambient temperature, at which point the samples were centrifuged at
904 21,000 x g for 10 min at 4°C. The supernatant was removed, and the pellet was resuspended in
905 either buffer alone or buffer with 25% PEG 3350 (final concentration); the presence or absence
906 of 25% PEG 3350 and the buffer identity of the resuspension solution corresponded to the initial
907 sample preparation. To neutralize the buffer, 10 µL of 1 M Tris (pH 6.8) was added to each
908 sample before running on an SDS-PAGE gel and staining with Coomassie blue. Images of the
909 gels were obtained on the BioRad Gel Doc EZ Gel Documentation System with Image Lab™
910 Software. Representative images are shown. ImageJ was used to quantify the bands, which
911 were plotted in GraphPad Prism.

912 Steady-state kinetic analyses were also performed at each pH in 25% PEG 3350. A
913 constant concentration of 2.5 µM TIR was used in these assays. Reaction components were
914 mixed in quadruplicate and incubated at room temperature for 10 min before initiating the
915 reaction with 0-2000 µM of ε-NAD (final concentration). Fluorescence intensity was monitored
916 every 15 sec for 15 min. Using the ε-ADPR standard curve, the fluorescence was converted to
917 [ε-ADPR]. The velocity of the reactions was calculated from the slope of the progress curve at
918 each ε-NAD concentration. Kinetic parameters were determined by fitting these velocities to the

Michaelis-Menten equation (Eq. 1) at each pH. The log of K_m , k_{cat} , and k_{cat}/K_m values were determined and plotted in GraphPad Prism.

Negative Stain Electron Microscopy. Negative stain EM on TIR (270 $\mu\text{g/mL}$) was performed in Assay Buffer (50 mM Tris, pH 8; 150 mM NaCl) with or without 500 mM sodium citrate. Samples were applied to glow-discharged, carbon- and formvar-coated copper grids and allowed to sit for 1 min and 30s before blotting excess liquid away. 1% uranyl acetate was used to fix the samples before imaging. Samples were imaged on an FEI Tecnai Spirit 12 microscope. The diameters of particles in the samples with citrate were analyzed in ImageJ.

TIR domain mutants. TIR domain mutants were made using PCR-based methods. The pET30a+ TIR-1 TIR domain construct was used as a template (0.2-2 ng/ μL ; final concentration). The manufacturer's protocol for iProofTM High-Fidelity DNA Polymerase (Bio-Rad Laboratories, Inc.) was followed using iProof HF buffer supplemented with 3% DMSO. 50- μL reaction volumes were used in the following protocol: initial denaturation for 3 min at 98°C, denaturation for 45 s at 98°C, annealing for 1:30 min at 45-72 °C, extension for 6 min at 72°C, final extension for 10 min at 72°C. Denaturation, annealing, and extension steps were repeated 30 times. The following day, *DpnI* was added to the PCR reactions and incubated at 37°C for 2 h to digest the template DNA. The digest was transformed into chemically competent *E. coli* XL1-Blue cells. Transformants were grown overnight in LB media with 50 $\mu\text{g/mL}$ kanamycin and mini-prepped (Promega). Mutagenesis was validated by Sanger sequencing (Genewiz). The mutants were expressed and purified as described for WT TIR.

Steady-state kinetic analyses of the mutants were carried out in Assay Buffer with 25% PEG 3350 or 500 mM sodium citrate with 2.5 μM of the mutants (final concentrations). Reaction components were mixed in triplicate and incubated at room temperature for 10 min before initiating the reaction with 0-2000 μM of ϵ -NAD for PEG 3350 or 0-4000 μM for citrate.

Fluorescence intensity was monitored every 15 sec for 17.5 min. Using the ϵ -ADPR standard curve, the fluorescence was converted to [ϵ -ADPR]. The velocity of the reactions was calculated from the slope of the progress curve at each ϵ -NAD concentration and plotted in GraphPad Prism. Kinetic parameters were determined by fitting these velocities to the Michaelis-Menten equation (Eq. 1) for each mutant.

To evaluate the precipitation capacity of TIR mutants, 10 μ M (WT, G747P, E788Q, and H833A) or 3 μ M (WT, E788A) of the enzyme was mixed with Assay Buffer (50 mM Tris, pH 8.0; 150 NaCl) with and without 25% PEG 3350 or 500 mM sodium citrate (final concentrations). Precipitation of the TIR^{E788A} mutant was evaluated at 3 μ M due to low yields of the protein; WT TIR at 3 μ M was included as the proper control. The samples were incubated for 15 min at ambient temperature, at which point the samples were centrifuged at 21,000 $\times g$ for 10 min at 4°C. The supernatant was removed, and the pellet was resuspended buffer with the respective additive (final concentration). Samples were diluted 1:1 with water before running on an SDS-PAGE gel. Stain-free images of the gels were obtained on the BioRad Gel Doc EZ Gel Documentation System with Image LabTM Software. Representative images are shown. ImageJ was used to quantify the bands, which were plotted in GraphPad Prism.

Statistical Analyses. Differences in the survival of *C. elegans* in the *P. aeruginosa* pathogenesis assays were determined with the log-rank test after survival curves were estimated for each group with the Kaplan-Meier method. OASIS 2 was used for these statistical analyses (99). qRT-PCR studies, intestinal CFU quantification, western blot band intensity quantification, TIR NADase activity, and TIR protein precipitation are presented as the mean $\pm$ standard error of the mean. Statistical hypothesis testing was performed with Prism 9 (GraphPad Software) using methods indicated in the figure legends. Sample sizes, mean lifespan, and p-values for all trials are shown in Supplementary file 4.

970

971 **Data Availability.** The mRNA-seq datasets are available from the NCBI Gene Expression
972 Omnibus using the accession numbers GSE178572 and GSE190585. All other data are
973 available in the manuscript.

974

975 **REFERENCES**

- 976 1. Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, Inoue H, et al. A conserved p38
977 MAP kinase pathway in *Caenorhabditis elegans* innate immunity. *Science*. 2002;297(5581):623-
978 6.
- 979 2. Troemel ER, Chu SW, Reinke V, Lee SS, Ausubel FM, Kim DH. p38 MAPK regulates
980 expression of immune response genes and contributes to longevity in *C. elegans*. *PLoS Genet*.
981 2006;2(11):e183.
- 982 3. Peterson ND, Pukkila-Worley R. *Caenorhabditis elegans* in high-throughput screens for anti-
983 infective compounds. *Curr Opin Immunol*. 2018;54:59-65.
- 984 4. Pukkila-Worley R, Ausubel FM. Immune defense mechanisms in the *Caenorhabditis elegans*
985 intestinal epithelium. *Curr Opin Immunol*. 2012;24(1):3-9.
- 986 5. Zhang X, Dodds PN, Bernoux M. What Do We Know About NOD-Like Receptors in Plant
987 Immunity? *Annu Rev Phytopathol*. 2017;55:205-29.
- 988 6. Ve T, Williams SJ, Kobe B. Structure and function of Toll/interleukin-1 receptor/resistance
989 protein (TIR) domains. *Apoptosis*. 2015;20(2):250-61.
- 990 7. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like
991 receptor signalling. *Nat Rev Immunol*. 2007;7(5):353-64.
- 992 8. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like
993 receptor signalling complexes. *Nat Rev Immunol*. 2014;14(8):546-58.
- 994 9. Lolle S, Stevens D, Coaker G. Plant NLR-triggered immunity: from receptor activation to
995 downstream signaling. *Curr Opin Immunol*. 2020;62:99-105.
- 996 10. Liberati NT, Fitzgerald KA, Kim DH, Feinbaum R, Golenbock DT, Ausubel FM.
997 Requirement for a conserved Toll/interleukin-1 resistance domain protein in the *Caenorhabditis*
998 *elegans* immune response. *Proc Natl Acad Sci USA*. 2004;101(17):6593-8.
- 999 11. Couillault C, Pujol N, Reboul J, Sabatier L, Guichou JF, Kohara Y, et al. TLR-independent
1000 control of innate immunity in *Caenorhabditis elegans* by the TIR domain adaptor protein TIR-1,
1001 an ortholog of human SARM. *Nat Immunol*. 2004;5(5):488-94.
- 1002 12. Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1
1003 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD(+) Cleavage Activity that
1004 Promotes Pathological Axonal Degeneration. *Neuron*. 2017;93(6):1334-43.e5.
- 1005 13. Wan L, Essuman K, Anderson RG, Sasaki Y, Monteiro F, Chung EH, et al. TIR domains of
1006 plant immune receptors are NAD(+)-cleaving enzymes that promote cell death. *Science*.
1007 2019;365(6455):799-803.

14. Horsefield S, Burdett H, Zhang X, Manik MK, Shi Y, Chen J, et al. NAD(+) cleavage activity by animal and plant TIR domains in cell death pathways. *Science*. 2019;365(6455):793-9.
15. Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD(+) destruction. *Science*. 2015;348(6233):453-7.
16. Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. *J Neurosci*. 2013;33(33):13569-80.
17. Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. *Science*. 2018;361(6403):704-9.
18. Chen D, Wang Z, Zhao YG, Zheng H, Zhao H, Liu N, et al. Inositol Polyphosphate Multikinase Inhibits Liquid-Liquid Phase Separation of TFEB to Negatively Regulate Autophagy Activity. *Dev Cell*. 2020;55(5):588-602 e7.
19. Alberti S, Gladfelter A, Mittag T. Considerations and Challenges in Studying Liquid-Liquid Phase Separation and Biomolecular Condensates. *Cell*. 2019;176(3):419-34.
20. Boeynaems S, Alberti S, Fawzi NL, Mittag T, Polymenidou M, Rousseau F, et al. Protein Phase Separation: A New Phase in Cell Biology. *Trends Cell Biol*. 2018;28(6):420-35.
21. Alberti S, Dormann D. Liquid-Liquid Phase Separation in Disease. *Annu Rev Genet*. 2019;53:171-94.
22. Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. *Cell*. 2015;162(5):1066-77.
23. Verdile V, De Paola E, Paronetto MP. Aberrant Phase Transitions: Side Effects and Novel Therapeutic Strategies in Human Disease. *Front Genet*. 2019;10:173.
24. Kroschwald S, Maharana S, Mateju D, Malinovska L, Nuske E, Poser I, et al. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. *Elife*. 2015;4:e06807.
25. Loring HS, Czech VL, Icsó JD, O'Connor L, Parelkar SS, Byrne AB, et al. A phase transition enhances the catalytic activity of SARM1, an NAD(+) glycohydrolase involved in neurodegeneration. *Elife*. 2021;10.
26. Magner DB, Wollam J, Shen Y, Hoppe C, Li D, Latza C, et al. The NHR-8 nuclear receptor regulates cholesterol and bile acid homeostasis in *C. elegans*. *Cell Metab*. 2013;18(2):212-24.
27. Hieb WF, Rothstein M. Sterol requirement for reproduction of a free-living nematode. *Science*. 1968;160(3829):778-80.

28. Chitwood DJ. Biochemistry and function of nematode steroids. *Crit Rev Biochem Mol Biol.* 1999;34(4):273-84.
29. Shim YH, Chun JH, Lee EY, Paik YK. Role of cholesterol in germ-line development of *Caenorhabditis elegans*. *Mol Reprod Dev.* 2002;61(3):358-66.
30. Merris M, Wadsworth WG, Khamrai U, Bittman R, Chitwood DJ, Lenard J. Sterol effects and sites of sterol accumulation in *Caenorhabditis elegans*: developmental requirement for 4alpha-methyl sterols. *J Lipid Res.* 2003;44(1):172-81.
31. Yochem J, Tuck S, Greenwald I, Han M. A gp330/megalin-related protein is required in the major epidermis of *Caenorhabditis elegans* for completion of molting. *Development.* 1999;126(3):597-606.
32. Otarigho B, Aballay A. Cholesterol Regulates Innate Immunity via Nuclear Hormone Receptor NHR-8. *iScience.* 2020;23(5):101068.
33. Cheong MC, Na K, Kim H, Jeong SK, Joo HJ, Chitwood DJ, et al. A potential biochemical mechanism underlying the influence of sterol deprivation stress on *Caenorhabditis elegans* longevity. *J Biol Chem.* 2011;286(9):7248-56.
34. Burnell AM, Houthoofd K, O'Hanlon K, Vanfleteren JR. Alternate metabolism during the dauer stage of the nematode *Caenorhabditis elegans*. *Exp Gerontol.* 2005;40(11):850-6.
35. Vanfleteren JR, De Vreese A. Rate of aerobic metabolism and superoxide production rate potential in the nematode *Caenorhabditis elegans*. *J Exp Zool.* 1996;274(2):93-100.
36. Gerisch B, Weitzel C, Kober-Eisermann C, Rottiers V, Antebi A. A hormonal signaling pathway influencing *C. elegans* metabolism, reproductive development, and life span. *Dev Cell.* 2001;1(6):841-51.
37. Gerisch B, Antebi A. Hormonal signals produced by DAF-9/cytochrome P450 regulate *C. elegans* dauer diapause in response to environmental cues. *Development.* 2004;131(8):1765-76.
38. Motola DL, Cummins CL, Rottiers V, Sharma KK, Li T, Li Y, et al. Identification of ligands for DAF-12 that govern dauer formation and reproduction in *C. elegans*. *Cell.* 2006;124(6):1209-23.
39. Chuang CF, Bargmann CI. A Toll-interleukin 1 repeat protein at the synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK signaling. *Genes Dev.* 2005;19(2):270-81.
40. Shivers RP, Kooistra T, Chu SW, Pagano DJ, Kim DH. Tissue-specific activities of an immune signaling module regulate physiological responses to pathogenic and nutritional bacteria in *C. elegans*. *Cell Host Microbe.* 2009;6(4):321-30.

41. Summers DW, Gibson DA, DiAntonio A, Milbrandt J. SARM1-specific motifs in the TIR domain enable NAD⁺ loss and regulate injury-induced SARM1 activation. *Proc Natl Acad Sci U S A*. 2016;113(41):E6271-e80.
42. Gadda G, Sobrado P. Kinetic Solvent Viscosity Effects as Probes for Studying the Mechanisms of Enzyme Action. *Biochemistry*. 2018;57(25):3445-53.
43. Blacklow SC, Raines RT, Lim WA, Zamore PD, Knowles JR. Triosephosphate isomerase catalysis is diffusion controlled. Appendix: Analysis of triose phosphate equilibria in aqueous solution by 31P NMR. *Biochemistry*. 1988;27(4):1158-67.
44. Rivas G, Minton AP. Macromolecular Crowding In Vitro, In Vivo, and In Between. *Trends Biochem Sci*. 2016;41(11):970-81.
45. Peskett TR, Rau F, O'Driscoll J, Patani R, Lowe AR, Saibil HR. A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation. *Mol Cell*. 2018;70(4):588-601 e6.
46. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974;77(1):71-94.
47. Bolz DD, Tenor JL, Aballay A. A conserved PMK-1/p38 MAPK is required in *Caenorhabditis elegans* tissue-specific immune response to *Yersinia pestis* infection. *J Biol Chem*. 2010;285(14):10832-40.
48. Lindblom TH, Pierce GJ, Sluder AE. A *C. elegans* orphan nuclear receptor contributes to xenobiotic resistance. *Curr Biol*. 2001;11(11):864-8.
49. Otarigho B, Aballay A. Erratum: Cholesterol Regulates Innate Immunity via Nuclear Hormone Receptor NHR-8. *iScience*. 2021;24(11):103361.
50. Shivers RP, Pagano DJ, Kooistra T, Richardson CE, Reddy KC, Whitney JK, et al. Phosphorylation of the conserved transcription factor ATF-7 by PMK-1 p38 MAPK regulates innate immunity in *Caenorhabditis elegans*. *PLoS Genet*. 2010;6(4):e1000892.
51. Inoue H, Hisamoto N, An JH, Oliveira RP, Nishida E, Blackwell TK, et al. The *C. elegans* p38 MAPK pathway regulates nuclear localization of the transcription factor SKN-1 in oxidative stress response. *Genes Dev*. 2005;19(19):2278-83.
52. Kim DH, Liberati NT, Mizuno T, Inoue H, Hisamoto N, Matsumoto K, et al. Integration of *Caenorhabditis elegans* MAPK pathways mediating immunity and stress resistance by MEK-1 MAPK kinase and VHP-1 MAPK phosphatase. *Proc Natl Acad Sci USA*. 2004;101(30):10990-4.
53. Powell JR, Kim DH, Ausubel FM. The G protein-coupled receptor FSHR-1 is required for the *Caenorhabditis elegans* innate immune response. *Proc Natl Acad Sci U S A*. 2009;106(8):2782-7.

54. Garsin DA, Villanueva JM, Begun J, Kim DH, Sifri CD, Calderwood SB, et al. Long-lived *C. elegans daf-2* mutants are resistant to bacterial pathogens. *Science*. 2003;300(5627):1921.
55. Marion CM, McDaniel DP, Armstrong RC. Sarm1 deletion reduces axon damage, demyelination, and white matter atrophy after experimental traumatic brain injury. *Exp Neurol*. 2019;321:113040.
56. Henninger N, Bouley J, Sikoglu EM, An J, Moore CM, King JA, et al. Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. *Brain*. 2016;139(Pt 4):1094-105.
57. Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. *Brain*. 2016;139(Pt 12):3092-108.
58. Bratkowski M, Xie T, Thayer DA, Lad S, Mathur P, Yang YS, et al. Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1. *Cell Rep*. 2020;32(5):107999.
59. Jiang Y, Liu T, Lee CH, Chang Q, Yang J, Zhang Z. The NAD(+)-mediated self-inhibition mechanism of pro-neurodegenerative SARM1. *Nature*. 2020;588(7839):658-63.
60. Zhao ZY, Xie XJ, Li WH, Liu J, Chen Z, Zhang B, et al. A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death. *iScience*. 2019;15:452-66.
61. Peterson ND, Cheesman HK, Liu P, Anderson SM, Foster KJ, Chhaya R, et al. The nuclear hormone receptor NHR-86 controls anti-pathogen responses in *C. elegans*. *PLoS Genet*. 2019;15(1):e1007935.
62. Sluder AE, Mathews SW, Hough D, Yin VP, Maina CV. The nuclear receptor superfamily has undergone extensive proliferation and diversification in nematodes. *Genome Res*. 1999;9(2):103-20.
63. Sluder AE, Maina CV. Nuclear receptors in nematodes: themes and variations. *Trends Genet*. 2001;17(4):206-13.
64. Pujol N, Cypowyj S, Ziegler K, Millet A, Astrain A, Goncharov A, et al. Distinct innate immune responses to infection and wounding in the *C. elegans* epidermis. *Curr Biol*. 2008;18(7):481-9.
65. Tecle E, Chhan CB, Franklin L, Underwood RS, Hanna-Rose W, Troemel ER. The purine nucleoside phosphorylase *pnp-1* regulates epithelial cell resistance to infection in *C. elegans*. *PLoS Pathog*. 2021;17(4):e1009350.

66. Foster KJ, Cheesman HK, Liu P, Peterson ND, Anderson SM, Pukkila-Worley R. Innate Immunity in the *C. elegans* Intestine Is Programmed by a Neuronal Regulator of AWC Olfactory Neuron Development. *Cell Rep.* 2020;31(1):107478.
67. Wu Z, Isik M, Moroz N, Steinbaugh MJ, Zhang P, Blackwell TK. Dietary Restriction Extends Lifespan through Metabolic Regulation of Innate Immunity. *Cell Metab.* 2019;29(5):1192-205 e8.
68. Anderson SM, Pukkila-Worley R. Immunometabolism in *Caenorhabditis elegans*. *PLoS Pathog.* 2020;16(10):e1008897.
69. Styer KL, Singh V, Macosko E, Steele SE, Bargmann CI, Aballay A. Innate immunity in *Caenorhabditis elegans* is regulated by neurons expressing NPR-1/GPCR. *Science.* 2008;322(5900):460-4.
70. Cao X, Aballay A. Neural Inhibition of Dopaminergic Signaling Enhances Immunity in a Cell-Non-autonomous Manner. *Curr Biol.* 2016;26(17):2329-34.
71. Cao X, Kajino-Sakamoto R, Doss A, Aballay A. Distinct Roles of Sensory Neurons in Mediating Pathogen Avoidance and Neuropeptide-Dependent Immune Regulation. *Cell Rep.* 2017;21(6):1442-51.
72. Sun J, Singh V, Kajino-Sakamoto R, Aballay A. Neuronal GPCR controls innate immunity by regulating noncanonical unfolded protein response genes. *Science.* 2011;332(6030):729-32.
73. Mizuno T, Hisamoto N, Terada T, Kondo T, Adachi M, Nishida E, et al. The *Caenorhabditis elegans* MAPK phosphatase VHP-1 mediates a novel JNK-like signaling pathway in stress response. *EMBO J.* 2004;23(11):2226-34.
74. Pukkila-Worley R, Feinbaum RL, McEwan DL, Conery AL, Ausubel FM. The evolutionarily conserved mediator subunit MDT-15/MED15 links protective innate immune responses and xenobiotic detoxification. *PLoS Pathog.* 2014;10(5):e1004143.
75. Henderson ST, Johnson TE. *daf-16* integrates developmental and environmental inputs to mediate aging in the nematode *Caenorhabditis elegans*. *Curr Biol.* 2001;11(24):1975-80.
76. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. *Science.* 1995;268(5219):1899-902.
77. Anderson SM, Cheesman HK, Peterson ND, Salisbury JE, Soukas AA, Pukkila-Worley R. The fatty acid oleate is required for innate immune activation and pathogen defense in *Caenorhabditis elegans*. *PLoS Pathog.* 2019;15(6):e1007893.
78. Nandakumar M, Tan MW. Gamma-Linolenic and Stearidonic Acids Are Required for Basal Immunity in *Caenorhabditis elegans* through Their Effects on p38 MAP Kinase Activity. *PLoS Genet.* 2008;4(11):e1000273.

79. Dokshin GA, Ghanta KS, Piscopo KM, Mello CC. Robust Genome Editing with Short Single-Stranded and Long, Partially Single-Stranded DNA Donors in *Caenorhabditis elegans*. Genetics. 2018;210(3):781-7.
80. Ghanta KS, Mello CC. Melting dsDNA Donor Molecules Greatly Improves Precision Genome Editing in *Caenorhabditis elegans*. Genetics. 2020;216(3):643-50.
81. Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 2019;47(W1):W171-W4.
82. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature. 1998;391(6669):806-11.
83. Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. Gene. 2001;263(1-2):103-12.
84. Conte D, Jr., MacNeil LT, Walhout AJM, Mello CC. RNA Interference in *Caenorhabditis elegans*. Curr Protoc Mol Biol. 2015;109:26 3 1- 3 30.
85. Tan MW, Mahajan-Miklos S, Ausubel FM. Killing of *Caenorhabditis elegans* by *Pseudomonas aeruginosa* used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci USA. 1999;96(2):715-20.
86. Foster KJ, McEwan DL, Pukkila-Worley R. Measurements of Innate Immune Function in *C. elegans*. Methods Mol Biol. 2020;2144:145-60.
87. Singh J, Aballay A. Microbial Colonization Activates an Immune Fight-and-Flight Response via Neuroendocrine Signaling. Dev Cell. 2019;49(1):89-99 e4.
88. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525-7.
89. Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods. 2017;14(7):687-90.
90. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
91. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.
92. Fletcher M, Tillman EJ, Butty VL, Levine SS, Kim DH. Global transcriptional regulation of innate immunity by ATF-7 in *C. elegans*. PLoS Genet. 2019;15(2):e1007830.

93. Taubert S, Hansen M, Van Gilst MR, Cooper SB, Yamamoto KR. The Mediator subunit MDT-15 confers metabolic adaptation to ingested material. *PLoS Genet.* 2008;4(2):e1000021.
94. Richardson CE, Kooistra T, Kim DH. An essential role for XBP-1 in host protection against immune activation in *C. elegans*. *Nature.* 2010;463(7284):1092-5.
95. Estes KA, Dunbar TL, Powell JR, Ausubel FM, Troemel ER. bZIP transcription factor *zip-2* mediates an early response to *Pseudomonas aeruginosa* infection in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A.* 2010;107(5):2153-8.
96. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 2001;29(9):e45.
97. Cheesman HK, Feinbaum RL, Thekkiniath J, Downen RH, Conery AL, Pukkila-Worley R. Aberrant Activation of p38 MAP Kinase-Dependent Innate Immune Responses Is Toxic to *Caenorhabditis elegans*. *G3 (Bethesda).* 2016;6(3):541-9.
98. Loring HS, Icsó JD, Nemmara VV, Thompson PR. Initial Kinetic Characterization of Sterile Alpha and Toll/Interleukin Receptor Motif-Containing Protein 1. *Biochemistry.* 2020;59(8):933-42.
99. Han SK, Lee D, Lee H, Kim D, Son HG, Yang JS, et al. OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research. *Oncotarget.* 2016;7(35):56147-52.

Figure 1. Multimerization of TIR-1/SARM1 and its intrinsic NAD⁺ glycohydrolase activity are required for activation of the p38 PMK-1 innate immune pathway during pathogen infection. (A) Images of animals expressing TIR-1::wrmScarlet in the indicated conditions. All *tir-1::wrmScarlet* animals were treated with *glo-3(RNAi)* to deplete autofluorescent gut granules. Representative images for each condition are displayed. Red fluorescent channel images display both TIR-1::wrmScarlet fluorescence and autofluorescent signal, while the green fluorescent channel images only display signals from autofluorescent gut granules. TIR-1::wrmScarlet puncta are indicated by arrowheads and autofluorescent gut granules by asterisks. **(B)** The number of puncta present in the last posterior pair of intestinal epithelial cells in the red (*tir-1::wrmScarlet*), but not the green (autofluorescence) fluorescent channels were quantified using Fiji image analysis software. Each data point is the number of TIR-1::wrmScarlet puncta from one animal. The n is indicated for each condition. *equals p<0.05 (two-way ANOVA with Tukey's multiple comparison testing). **(C)** Model of *tir-1* showing the domains and the mutations that were introduced using CRISPR-Cas9. **(D)** Expression of the innate immune effector T24B8.5p::gfp in *tir-1* mutants with predicted defects in oligomerization (*tir-1*^{ΔSAM}, *tir-1*^{G747P} and *tir-1*^{H833A}) and NADase catalytic activity (*tir-1*^{E788A}) during *P. aeruginosa* infection. Scale bar equals 20 μm (2 μm for the inset enlarged images). **(E)** Immunoblot analysis of lysates from the indicated genotypes probed with antibodies targeting the doubly phosphorylated TGY epitope in phosphorylated PMK-1 (phos-PMK-1), total PMK-1 protein (total PMK-1), and tubulin (α-tubulin). *nsy-1(ag3)* and *pmk-1(km25)* loss-of-function mutants are the controls, which confirm the specificity of the phospho-PMK-1 probing. **(F)** The band intensities of three biological replicates of the Western blot shown in **(E)** were quantified. Error bars reflect SEM. *equals p<0.05 (one-way ANOVA with Dunnett multiple comparison testing). **(G)** *C. elegans* pathogenesis assay with *P. aeruginosa* and *C. elegans* of indicated genotypes at the L4 larval stage are shown. Data are representative of three trials. Difference between wild-type and all *tir-1* mutants is significant (p<0.05). The Kaplan-Meier method was used to estimate the survival curves for each group, and the log-rank test was used for all statistical comparisons. Sample sizes, mean lifespan and p-values for all trials are shown in Supplementary file 4. See also Fig. 1 – figure supplement 1.

Figure 2. TIR multimerization and phase transition superactivates its intrinsic NAD⁺ glycohydrolase activity. (A) NADase activity of purified TIR at increasing TIR protein concentrations is shown. Activity was assessed by incubating TIR protein with 1 mM ϵ -NAD and monitoring the rate at which the fluorescent product ϵ -ADPR was produced. Curve represents a nonlinear regression fit of the NADase activity data points (n=2). (B) NADase activity of 2.5 μ M TIR incubated in the presence of 25% (w/v) of macro- (PEG 8000, PEG 3350 and dextran) and micro- (sucrose and glycerol) viscosogens was assessed as described in Fig. 2A (n=2). (C) Dose dependency of macroviscosogens on the NADase activity of TIR is shown. 2.5 μ M TIR protein was incubated with the indicated PEG compounds at concentrations from 0-30% (w/v). NADase activity was assessed as described in Fig. 2A (n=2). (D) Steady-state kinetic analysis of 2.5 μ M TIR incubated in 0-30% (w/v) of PEG 3350 with the ϵ -NAD substrate at concentrations from 0-4000 μ M was assessed as described in Fig. 2A. (n=2). From the steady-state kinetic analysis performed in Fig. 2D, K_m (E), k_{cat} (F), and k_{cat}/K_m (G) were determined at each PEG 3350 concentration. (H) SDS-PAGE analysis of TIR protein fractions incubated with increasing concentrations of PEG 3350 precentrifugation (C) and after centrifugation, the soluble (S) and pellet (P) protein fractions. NADase activity of TIR protein in each fraction and at each concentration of PEG 3350 was assessed, as described in Fig. 2A, and is represented below the gel image (n=2, representative image shown). (I) Steady-state kinetic analysis of TIR wild-type, oligomerization mutants (TIR^{G747P} and TIR^{H833A}), and catalytic mutants (TIR^{E788Q} and TIR^{E788A}) in 25% PEG 3350 with 0-2000 μ M ϵ -NAD was assessed as described in Fig. 2D. The inset image outlined in red is an enlarged image of the mutant kinetic data. Kinetic parameters (K_m , k_{cat} , and k_{cat}/K_m) are shown in the table below the graph (n=3). (J, K) SDS-PAGE analysis of TIR wild-type, oligomerization mutant (TIR^{G747P}) and catalytic mutants (TIR^{E788Q} and TIR^{E788A}) precipitation in the presence of 25% PEG 3350. Gel represents the soluble (S) and pellet (P) protein fractions of wild-type and mutant TIR following incubation with PEG 3350 and centrifugation. TIR^{G747P} and TIR^{E788Q} were assessed with 10 μ M protein in Fig. 2J, and TIR^{E788A} was assessed with 3 μ M protein in Fig. 2K (a lower concentration was used for TIR^{E788A} assays because the yield of the purified TIR^{E788A} mutant was low). Quantification of replicates represented below gel images (n=4, representative images shown). *equals $p < 0.05$ by one-way ANOVA in Fig. 2J and unpaired t-test in Fig. 2K. (L) Effect of 1,6-hexanediol on TIR NADase activity is shown. TIR protein was incubated in the presence or absence of either 25% PEG 3350 or 500 mM citrate and treated with either 0 or 2% 1,6-hexanediol. The NADase activity of TIR for each condition was assessed using the ϵ -NAD substrate assay (n=3). *equals $p < 0.05$ (unpaired t-test). (M) The NADase activity of TIR protein incubated with either 25% PEG 3350 or 500 mM citrate before (precentrifugation, n=2) and after centrifugation, the supernatant (n=4) and precipitant (n=2) fractions. Precipitation fractions were resuspended in buffer alone or buffer containing 25% PEG 3350 or 500 mM citrate, and NADase activity was assessed. (N) Negative stain electron microscopy in either the absence or presence of 500 mM citrate (diameter of particles = 8.9 nm $\pm$ 1.2, n = 65). Representative circular particles are labeled with arrowheads. All error bars reflect SEM. See also Fig. 2 – figure supplements 1 and 2.

Figure 3. Cholesterol scarcity activates intestinal innate immune defenses. Images of T24B8.5p::*gfp* (**A**) and *irg-5p::GFP* (**B**) transcriptional immune reporters in wild-type animals grown on standard nematode growth media (+5 µg/mL cholesterol) and in the absence of supplemented cholesterol (+0 µg/mL cholesterol). (**C**) qRT-PCR data of the indicated innate immune effector genes in wild-type *C. elegans* grown in the presence (+5 µg/mL) and absence (+0 µg/mL) of supplemented cholesterol. *equals $p < 0.05$ (unpaired t-test). (**D and E**) Data from mRNA-seq experiments comparing genes differentially regulated in uninfected *nhr-8(hd117)* mutants versus wild-type animals (**D**) or uninfected wild-type animals grown in the absence (0 µg/mL) versus presence (5 µg/mL) of supplemental cholesterol (**E**) (y-axis) are compared with genes differentially expressed in wild-type animals during *P. aeruginosa* infection (x-axis). All genes are shown in gray. Genes that are differentially expressed in both datasets are shown in black (Fold change > 2 , $q < 0.01$). Genes that are annotated as innate immune genes are shown in red. The location of the representative genes T24B8.5, *irg-5*, *irg-4*, and K08D8.4, whose expression is examined throughout this manuscript, are shown. (Of note, K08D8.4 did not meet our cut-off threshold, though was significantly upregulated, fold change = 1.79, $q = 5.6 \times 10^{-4}$). See also Supplementary files 1-3. (**F, G, H**) Images of T24B8.5p::*gfp* animals of the indicated genotypes grown under the indicated conditions are shown. (**H**) *C. elegans* were grown on media solidified with agarose rather than agar. (**I, J, K, L**) qRT-PCR data of the indicated genes in wild-type and *nhr-8(hd117)* mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol) in the presence or absence of 0.1% Tergitol, as indicated. For the qRT-PCR studies in Figs. 3C, 3I, 3J, 3K, and 3L, data are the average of three to six independent biological replicates, each normalized to a control gene with error bars representing SEM and are presented as the value relative to the average expression from all replicates of the indicated gene in wild-type animals on standard nematode growth media (+5 µg/mL cholesterol). *equals $p < 0.05$ (two-way ANOVA with Tukey's multiple comparison testing). (**M, N**) Survival curves for *C. elegans* pathogenesis assays with *P. aeruginosa* and *C. elegans* of the indicated genotypes at the L4 larval stage and exposed to the indicated conditions. Data are representative of three trials. The difference between the *nhr-8(hd117)* mutant and the other conditions in both M and N is significant ($p < 0.05$). The Kaplan-Meier method was used to estimate the survival curves for each group, and the log-rank test was used for all statistical comparisons. Sample sizes, mean lifespan and p-values for all trials are shown in Supplementary file 4. (**O**) *P. aeruginosa*, isolated from the intestines of animals with the indicated genotypes, were quantified after 24 hours of bacterial infection. Data are colony-forming units (CFU) of *P. aeruginosa* and are presented as the average of 10 separate biological replicates, with each replicate containing 10-11 animals. *equals $p < 0.05$ (unpaired t-test). Scale bars in all images equal 200 µm. See also Fig. 3 – figure supplement 1.

Figure 4. Cholesterol scarcity activates the p38 PMK-1 innate immune pathway. (A) Gene set enrichment analysis (GSEA) of p38 PMK-1 targets in the 0 µg/mL cholesterol mRNA-seq experiment. Fold change in expression of significantly differentially expressed genes (fold-change >2 and q<0.01) in uninfected animals grown in the absence (0 µg/mL) versus presence (5 µg/mL) of supplemental cholesterol are ranked from higher expression (red) to lower expression (blue). Normalized enrichment score (NES) and q-value are indicated. p38 PMK-1 targets found in the transcriptional profile are indicated by hit number (97) in the left margin and black lines. **(B)** An immunoblot analysis of lysates from wild-type *C. elegans* grown on standard nematode growth media in the presence (+5 µg/mL cholesterol) and in the absence (+0 µg/mL cholesterol) of supplemented cholesterol using antibodies that recognize the doubly phosphorylated TGY motif of PMK-1 (phos-PMK-1), total PMK-1 protein (total PMK-1) and tubulin (α-tubulin) is shown. PMK-1 is a 43.9 kDa protein and tubulin is a 50 kDa protein. **(C)** The band intensities of four biological replicates of the Western blot shown in Fig. 4A were quantified. Error bars represent SEM. *equals p<0.05 (unpaired t-test) **(D)** GSEA of p38 PMK-1 targets in the *nhr-8* mRNA-seq experiment as described in Fig. 4A. **(E, F)** Western blot experiment **(E)** and quantification **(F)** of four biological replicate experiments as described in Figs. 4B and 4C with the strains of the indicated genotypes. In Figs. 4B and 4E, *pmk-1(km25)* and *nsy-1(ag3)* are loss-of-function mutants that serve as controls to confirm the specificity of phos-PMK-1 and total PMK-1 probing. Error bars represent SEM. *equals p<0.05 (one-way ANOVA with Dunnett's multiple comparison testing). **(G)** Images of T24B8.5p::*gfp* transcriptional immune reporter expression in wild-type animals and in *nhr-8(hd117)* mutants grown on control RNAi, *tir-1(RNAi)* or *atf-7(RNAi)* bacteria, as indicated. Quantification of GFP expression for this experiment is presented in Fig. 4 – figure supplement 1C. **(H, I, J, K)** qRT-PCR data of the indicated genes in the indicated mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol). Data are the average of three to seven independent replicates, each normalized to a control gene with error bars representing SEM and are presented as the value relative to the average expression from all replicates of the indicated gene in wild-type animals. *equals p<0.05 (one-way ANOVA with Dunnett's multiple comparison testing) **(L)** Images of T24B8.5p::*gfp* transcriptional immune reporter animals of the indicated genotypes grown in the presence or absence of 0.1% Tergitol. Scale bars in all images equal 200 µm. **(M)** Survival curves of *C. elegans* pathogenesis assay with *P. aeruginosa* and *C. elegans* of the indicated genotypes at the L4 larval stage exposed to the indicated conditions. Data are representative of three trials. Difference between *nhr-8(hd117)* and all other conditions is significant (p<0.05). The Kaplan-Meier method was used to estimate the survival curves for each group, and the log-rank test was used for all statistical comparisons. Sample sizes, mean lifespan and p-values for all trials are shown in Supplementary file 4. See also Fig. 4 – figure supplement 1.

Figure 5. Sterol stress activates the *C. elegans* p38 immune pathway through the multimerization and NAD⁺ glycohydrolase activity of TIR-1/SARM1. (A) Images of *tir-1::wrmScarlet* and *nhr-8(hd117);tir-1::wrmScarlet* animals as described in Fig. 1A exposed to either 0.1% Tergitol or *tir-1(RNAi)*. Scale bar equals 20 μ m (2 μ m for the inset enlarged images). (B) Quantification of the number of puncta present in the red (TIR-1::wrmScarlet), but not green (autofluorescence) channel with indicated conditions as described in Fig. 1B. *equals $p < 0.05$ (two-way ANOVA with Tukey's multiple comparison testing). (C,D) Images of T24B8.5p::gfp transcriptional immune reporter in *tir-1* mutants with defects in oligomerization (*tir-1* ^{Δ SAM}, *tir-1*^{G747P} and *tir-1*^{H833A}) and NADase catalytic activity (*tir-1*^{E788A}) following *nhr-8(RNAi)* (C), and during cholesterol deprivation (D). Scale bar equals 200 μ m. (E,F) qRT-PCR data of T24B8.5 (E) and *irg-4* (F) in wild-type and mutant animals of the indicated genotypes grown on standard nematode growth media (+5 μ g/mL cholesterol). Data are the average of three independent replicates, each normalized to a control gene with error bars representing SEM and are presented as the value relative to the average expression from all replicates in wild-type animals. *equals $p < 0.05$ (two-way ANOVA with Tukey's multiple comparison testing).

Figure 6. Sterol scarcity primes p38 PMK-1 immune defenses. (A, B, C, D, E) Images of the indicated transcriptional immune reporters under the indicated conditions. Scale bars in all images equal 200 μ m. (F) A heat map compares the expression levels of the 184 genes that were both induced in wild-type animals during *P. aeruginosa* infection and differentially expressed (either induced or repressed) in *nhr-8(hd117)* mutants at baseline (each greater than 2-fold, $q < 0.05$). To compare the expression of these genes in wild-type and *nhr-8(hd117)* mutants, we scaled the expression level in each condition by calculating a z-score for each row and performed hierarchical clustering, which identified two main clusters (Cluster I contains 139 genes and Cluster II contains 45 genes). See also Supplementary file 5. (G) Enrichment of p38 PMK-1-dependent genes in Cluster I and II genes is shown. (H, I, J, K) mRNA-seq data for the indicated genes from the experiment described in (F) showing scaled reads per base from three biological replicates. Error bars represent SEM. *equals $q < 0.05$ from RNA-seq analysis. (L) Model of p38 PMK-1 pathway activation during sterol scarcity and pathogen infection.

1486 **Figure 1 – figure supplement 1. Multimerization of TIR-1/SARM1 and its intrinsic NAD⁺**
1487 **glycohydrolase activity are required for activation of the p38 PMK-1 innate immune**
1488 **pathway during pathogen infection. (A)** Immunoblot analysis of lysates from the indicated
1489 genotypes probed with an antibody that recognizes the FLAG epitope. **(B)** Images of
1490 T24B8.5p::*gfp* immune reporter expression in the indicated genotypes. Scale bars in all images
1491 equal 200 μ m. See also Fig. 1.

Figure 2 – figure supplement 1. TIR multimerization and phase transition superactivates its intrinsic NAD⁺ glycohydrolase activity. (A) Enzyme concentration dependence in the presence and absence of either 25% PEG 3350 or 500 mM sodium citrate (n=2). (B) Dose-dependence of TIR NADase activity on citrate concentration as described in Fig. 2C, except using citrate (n=2). (C) Steady-state kinetic analysis of TIR as described in Fig. 2D, except in the presence of citrate (n=2). (D-F) From the steady-state kinetic analysis performed in (C), K_m (D), k_{cat} (E), and k_{cat}/K_m (F) were determined at each citrate concentration. (G) Effect of citrate on TIR aggregation and associated activity as described in Fig. 2H (n=2, representative images shown). (H) Steady-state kinetic analysis of TIR mutants as described in Fig. 2I, except in the presence of citrate (n=3). (I, J) Precipitation of TIR mutants as described in Fig. 2J and 2K, except in the presence of citrate (n=4, representative images shown). See also Fig. 2.

Figure 2 – figure supplement 2. TIR multimerization and phase transition superactivates its intrinsic NAD⁺ glycohydrolase activity. **(A)** SDS-PAGE analysis of TIR protein incubated first with 25% PEG 3350 or 500 mM citrate and subsequently with 2% 1,6-hexanediol; analysis was performed on TIR samples taken precentrifugation (C) or on the soluble (S) and pellet (P) fractions taken after centrifugation (n=2, representative image shown). **(B)** SDS-PAGE analysis of TIR protein incubated first with 0 or 2% 1,6-hexanediol and subsequently with 25% PEG 3350 or 500 mM citrate (n=2, representative image shown); analysis of protein fractions as in (A). **(C)** SDS-PAGE analysis of TIR protein in the soluble (S) and pellet (P) fractions following incubation with either PEG 3350 or citrate and centrifugation (1 spin). Pellet fractions were subsequently resuspended in only buffer or buffer containing 25% PEG 3350 or 500 mM citrate and centrifuged a second time to isolate the soluble (S) and pellet (P) fractions (n=2, representative image shown). **(D)** SDS-PAGE analysis of TIR in the soluble (S) and pellet (P) fractions incubated with or without 25% PEG 3350 at the indicated pH (n=2, representative image shown). TIR steady-state kinetic parameters [K_m **(E)**, k_{cat} **(F)**, k_{cat}/K_m **(G)**] are shown at the indicated pH (n=2). See also Fig. 2.

Figure 3 – figure supplement 1. Cholesterol scarcity activates intestinal innate immune defenses. (A) An mRNA-seq experiment as described in Fig. 3D, except using a different *nhr-8* mutant allele: *nhr-8(ok186)*. **(B)** Data from mRNA-seq experiments as described in Fig. 3D, except comparing genes differentially regulated in uninfected *nhr-8(hd117)* mutants versus wild-type animals (y-axis) with genes differentially expressed in uninfected wild-type animals grown in the absence (0 µg/mL) versus presence (5 µg/mL) of supplemental cholesterol (x-axis). **(C)** Images of T24B8.5p::*gfp* animals as described in Fig. 3G. **(D)** Images of T24B8.5p::*gfp* on agarose media with 0.1% Tergitol in the presence of supplemented fatty acids, as indicated. See also Fig. 3.

Figure 4 – figure supplement 1. Cholesterol scarcity activates the p38 PMK-1 innate immune pathway. (A) Gene set enrichment analysis (GSEA) of p38 PMK-1 targets in the mRNA-seq experiment as described in Fig 4D, except using a different *nhr-8* mutant allele: *nhr-8(ok186)*. **(B)** Images of T24B8.5p::*gfp* animals, as described in Fig. 4G. **(C)** Fiji was used to quantify the GFP fluorescence of individual animals in the indicated conditions. The n for each condition is presented in the figure and indicates the number of animals quantified. Error bars represent SEM. *equals $p < 0.05$ (one-way ANOVA with Tukey's multiple comparison testing). **(D)** Images of the transgenic *C. elegans*, in which *gfp* has been fused to the DAF-16 protein under the indicated conditions. Scale bars in all images equal 200 μm . See also Fig. 4.

Supplementary file 1. Genes significantly differentially expressed in uninfected *nhr-8(hd117)* mutants compared to wild-type animals in the RNA-seq experiments presented in Figs. 3D and Fig. 3 – figure supplement 1B.

Supplementary file 2. Genes significantly differentially expressed in uninfected *nhr-8(ok186)* mutants compared to wild-type animals in the RNA-seq experiments presented in Fig. 3 – figure supplement 1A.

Supplementary file 3. Genes significantly differentially expressed in uninfected wild-type animals in the absence (0 µg/mL) versus presence (5 µg/mL) of cholesterol supplementation in the RNA-seq experiments presented in Fig. 3E and Fig. 3 – figure supplement 1B.

Supplementary file 4. Sample sizes, mean lifespan, and p values for the *C. elegans* pathogenesis assays.

Supplementary file 5. Genes in Cluster 1 and Cluster 2 of the heat map shown in Fig. 6F.

Supplementary file 6. Primer, crRNA guide and ssODN sequences designed for this study.

Supplementary file 7. *pmk-1* dependent genes used for GSEA analysis

Source data 1: Raw and annotated gel and blot images

Figure 1 – source data 1: Figure 1B. Quantification of the number of TIR-1::wrmScarlet puncta present in the last posterior pair of intestinal epithelial cells.

Figure 1 – source data 2: Figure 1F. Quantification of p38 immunoblot analysis of lysates from the indicated genotypes.

Figure 2 – source data 1: Figure 2A. NADase activity of purified TIR at increasing TIR protein concentrations.

Figure 2 – source data 2: Figure 2B. NADase activity of 2.5 μ M TIR incubated in the presence of 25% (w/v) of macro- (PEG 8000, PEG 3350 and dextran) and micro- (sucrose and glycerol) viscogens.

Figure 2 – source data 3: Figure 2C. Dose dependency of macroviscogens on the NADase activity of TIR.

Figure 2 – source data 4: Figure 2D. Steady-state kinetic analysis of 2.5 μ M TIR incubated in 0-30% (w/v) of PEG 3350.

Figure 2 – source data 5: Figure 2H. NADase activity of TIR protein in each fraction and at each concentration of PEG 3350.

Figure 2 – source data 6: Figure 2I. Steady-state kinetic analysis of TIR wild-type, oligomerization mutant (TIR^{G747P}, TIR^{H833A}), and catalytic mutants (TIR^{E788Q} and TIR^{E788A}) in 25% PEG 3350.

Figure 2 – source data 7: Figure 2J. Quantification of SDS-PAGE analysis of TIR: wild-type, oligomerization mutant (TIR^{G747P}) and catalytic mutant (TIR^{E788Q}), precipitation in the presence of 25% PEG 3350.

Figure 2 – source data 8: Figure 2K. Quantification of SDS-PAGE analysis of TIR: wild-type and catalytic mutant (TIR^{E788A}), precipitation in the presence of 25% PEG 3350.

Figure 2 – source data 9: Figure 2L. Effect of 1,6-hexanediol on TIR NADase activity.

Figure 2 – source data 10: Figure 2M. NADase activity of TIR protein incubated with either 25% PEG 3350 or 500 mM citrate before (precentrifugation) and after centrifugation, the supernatant and precipitant fractions.

Figure 3 – source data 1: Figure 3C. qRT-PCR data of the indicated innate immune effector genes in wild-type *C. elegans* growing in the presence (+5 μ g/mL) and absence (+0 μ g/mL) of supplemented cholesterol.

Figure 3 – source data 2: Figure 3I. qRT-PCR data of T24B8.5 in wild-type and *nhr-8(hd117)* mutant animals grown on standard nematode growth media (+5 μ g/mL cholesterol) in the presence or absence of 0.1% Tergitol, as indicated.

Figure 3 – source data 3: Figure 3J. qRT-PCR data of *irg-4* in wild-type and *nhr-8(hd117)* mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol) in the presence or absence of 0.1% Tergitol, as indicated.

Figure 3 – source data 4: Figure 3K. qRT-PCR data of *irg-5* in wild-type and *nhr-8(hd117)* mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol) in the presence or absence of 0.1% Tergitol, as indicated.

Figure 3 – source data 5: Figure 3L. qRT-PCR data of K08D8.4 in wild-type and *nhr-8(hd117)* mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol) in the presence or absence of 0.1% Tergitol, as indicated.

Figure 3 – source data 6: Figure 3O. Colony forming units (CFUs) of *P. aeruginosa*, isolated from the intestines of animals with the indicated genotypes, quantified after 24 hours of bacterial infection.

Figure 4 – source data 1: Figure 4C. Quantification of p38 immunoblot analysis of lysates from wild-type *C. elegans* grown on standard nematode growth media in the presence (+5 µg/mL cholesterol) and in the absence (+0 µg/mL cholesterol) of supplemented cholesterol.

Figure 4 – source data 2: Figure 4F. Quantification of p38 immunoblot analysis of lysates from the indicated *C. elegans* strains.

Figure 4 – source data 3: Figure 4H. qRT-PCR data of T24B8.5 in the indicated mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 4 – source data 4: Figure 4I. qRT-PCR data of *irg-4* in the indicated mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 4 – source data 5: Figure 4J. qRT-PCR data of *irg-5* in the indicated mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 4 – source data 6: Figure 4K. qRT-PCR data of K08D8.4 in the indicated mutant animals grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 5 – source data 1: Figure 5B. Quantification of the number of TIR-1::wrmScarlet puncta present in the last posterior pair of intestinal epithelial cells in the indicated strains and conditions.

Figure 5 – source data 2: Figure 5E. qRT-PCR data of T24B8.5 in wild-type and mutant animals of the indicated genotypes grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 5 – source data 3: Figure 5F. qRT-PCR data of *irg-4* in wild-type and mutant animals of the indicated genotypes grown on standard nematode growth media (+5 µg/mL cholesterol).

Figure 6 – source data 1: Figure 6H. mRNA-seq data for T24B8.5 from the conditions indicated showing scaled reads per base.

Figure 6 – source data 2: Figure 6I. mRNA-seq data for *irg-4* from the conditions indicated showing scaled reads per base.

Figure 6 – source data 3: Figure 6J. mRNA-seq data for *irg-5* from the conditions indicated showing scaled reads per base.

Figure 6 – source data 4: Figure 6K. mRNA-seq data for K08D8.4 from the conditions indicated showing scaled reads per base.

Figure 2 – figure supplement 1 – source data 1: 1A. Enzyme concentration dependence in presence and absence of either 25% PEG 3350 or 500 mM sodium citrate.

Figure 2 – figure supplement 1 – source data 2: 1B. Dose dependency of citrate on the NADase activity of TIR.

Figure 2 – figure supplement 1 – source data 3: 1C. Steady-state kinetic analysis of 2.5 μ M TIR incubated in 0-1000 mM sodium citrate.

Figure 2 – figure supplement 1 – source data 4: 1G. NADase activity of TIR protein in each fraction and at each concentration of citrate.

Figure 2 – figure supplement 1 – source data 5: 1H. Steady-state kinetic analysis of TIR wild-type, oligomerization mutant (TIR^{G747P}, TIR^{H833A}), and catalytic mutants (TIR^{E788Q} and TIR^{E788A}) in 500 mM sodium citrate.

Figure 2 – figure supplement 1 – source data 6: 1I. Quantification of SDS-PAGE analysis of TIR: wild-type, oligomerization mutant (TIR^{G747P}) and catalytic mutant (TIR^{E788Q}), precipitation in the presence of 500 mM sodium citrate.

Figure 2 – figure supplement 1 – source data 7: 1J. Quantification of SDS-PAGE analysis of TIR: wild-type and catalytic mutant (TIR^{E788A}), precipitation in the presence of 500 mM sodium citrate.

Figure 4 – figure supplement 1 – source data 1: 1C. Quantification of T24B8.5p::*gfp* expression in the indicated conditions.

Key Resources Table				
Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Strain, strain background (<i>Escherichia coli</i>)	OP50	<i>Caenorhabditis</i> Genetics Center		
Strain, strain background (<i>Escherichia coli</i>)	HT115	<i>Caenorhabditis</i> Genetics Center		
Strain, strain background (<i>Escherichia coli</i>)	BL21 (DE3)	ThermoFisher Scientific	EC0114	Chemically competent
Strain, strain background (<i>Escherichia coli</i>)	XL1-Blue	Agilent	200249	Chemically competent
Strain, strain background (<i>Pseudomonas aeruginosa</i>)	UCBPP-PA14	PMID: 7604262		
Strain, strain background (<i>Caenorhabditis elegans</i>)	N2; wild-type	CGC, PMID: 4366476	WormBase ID: WBStrain00000001	Laboratory reference strain/wild type
Strain, strain background (<i>Caenorhabditis elegans</i>)	KU25	PMID: 15116070	WormBase ID: WBStrain00024040	Genotype: <i>pmk-1(km25) IV</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	AU3	PMID: 12142542	WormBase ID: WBStrain000000259	Genotype: <i>nsy-1(ag3) II</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	ZD101	PMID: 19837372	WormBase ID: WBStrain00040806	Genotype: <i>tir-1(qd4) III</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	AA968	PMID: 23931753		Genotype: <i>nhr-8(hd117) IV</i>

Strain, strain background (<i>Caenorhabditis elegans</i>)	AE501	PMID: 11516648	WormBase ID: WBStrain00000059	Genotype: <i>nhr-8(ok186) IV</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	AU78	PMID: 19837372	WormBase ID: WBStrain00000262	Genotype: <i>agls219</i> [T24B8.5p:: <i>gfp</i> :: <i>unc-54-3'UTR</i> ; <i>ttx-3p</i> :: <i>gfp</i> :: <i>unc-54-3'UTR</i>] <i>III</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	AU306	PMID: 24875643		Genotype: <i>agls44</i> [<i>irg-4p</i> :: <i>gfp</i> :: <i>unc-54-3'UTR</i> ; <i>myo-2p</i> :: <i>mCherry</i>]
Strain, strain background (<i>Caenorhabditis elegans</i>)	AY101	PMID: 20133945	WormBase ID: WBStrain00000322	Genotype: <i>acls101</i> [<i>pDB09.1(irg-5p</i> :: <i>gfp</i>); <i>pRF4(rol-6(su1006))</i>]
Strain, strain background (<i>Caenorhabditis elegans</i>)	TJ356	PMID: 11747825	WormBase ID: WBStrain00034892	Genotype: <i>zls356</i> [<i>daf-16p</i> :: <i>daf-16a/b</i> :: <i>gfp</i> + <i>pRF4(rol-6(su1006))</i>]
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW278	This study		Genotype: <i>nhr-8(hd117);agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW317	This study		Genotype: <i>tir-1(qd4);nhr-8(hd117)</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW339	This study		Genotype: <i>tir-1(ums47[E788A]);agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW369	This study		Genotype: <i>tir-1(ums54[ΔSAM]);agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW374	This study		Genotype: <i>tir-1(ums55[G747P]);agls219</i>

Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW381	This study		Genotype: <i>tir-1(ums56[H833A]); agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW386	This study		Genotype: <i>tir-1(ums57[tir-1::3xFLAG]); agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW387	This study		Genotype: <i>tir-1(ums58[tir-1[E788A]::3xFLAG]); agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW388	This study		Genotype: <i>tir-1(ums59[tir-1[ΔSAM]::3xFLAG]); agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW 389	This study		Genotype: <i>tir-1(ums60[tir-1[G747P]::3xFLAG]); agls219</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW403	This study		Genotype: <i>tir-1(ums63[tir-1::wormScarlet])</i>
Strain, strain background (<i>Caenorhabditis elegans</i>)	RPW404	This study		Genotype: <i>nhr-8(hd117);tir-1(ums63[tir-1::wormScarlet])</i>
Antibody	anti-total PMK-1 (rabbit polyclonal)	PMID: 30668573		WB(1:1000)
Antibody	anti-Phospho-p38 MAPK (Thr180/Tyr182) (rabbit polyclonal)	Cell Signaling Technology	9211	WB(1:1,000)
Antibody	anti-FLAG (mouse monoclonal)	Sigma-Aldrich	F1804	WB(1:1,000)
Antibody	anti-alpha-tubulin (mouse monoclonal)	Sigma-Aldrich	T5168	WB(1:2,000)

Antibody	anti-mouse IgG-HRP (goat polyclonal)	Abcam	ab6789	WB(1:10,000)
Antibody	anti-rabbit IgG-HRP (goat polyclonal)	Cell Signaling Technology	7074	WB(1:10,000)
Chemical compound, drug	Peptone	Gibco	211820	
Chemical compound, drug	Agar	Fisher	BP9744	
Chemical compound, drug	Cholesterol	Sigma Aldrich	C3045	
Chemical compound, drug	Tri-Reagent	Sigma Aldrich	T9424	
Chemical compound, drug	TERGITOL solution (Type NP-40)	Sigma Aldrich	NP40S	
Chemical compound, drug	RIPA Buffer	Cell Signaling Technology, Inc.	89900	
Chemical compound, drug	Halt Protease and Phosphatase inhibitor	ThermoFisher Scientific	78445	
Chemical compound, drug	NuPAGE LDS sample buffer	ThermoFisher Scientific	NP0007	
Chemical compound, drug	1,6-hexanediol	Sigma Aldrich	240117	

Chemical compound, drug	Nicotinamide 1,N ⁶ -ethenoadenine dinucleotide; ε-NAD	Sigma Aldrich	N2630	
Chemical compound, drug	PEG 400	Sigma Aldrich	91893	
Chemical compound, drug	PEG 1500	Sigma Aldrich	86101	
Chemical compound, drug	PEG 3350	Sigma Aldrich	88276	
Chemical compound, drug	PEG 8000	Sigma Aldrich	89510	
Chemical compound, drug	Dextran	Fisher Scientific	ICN16011010	
Chemical compound, drug	Sucrose	Sigma Aldrich	S0389	
Chemical compound, drug	Glycerol	Sigma Aldrich	G5516	
Chemical compound, drug	Sodium citrate	Sigma Aldrich	S4641	
Chemical compound, drug	Kanamycin	Research Products International	K22000	
Chemical compound, drug	IPTG	ThermoFisher Scientific	R0392	

Chemical compound, drug	Pierce™ EDTA-free protease inhibitor mini tablets	ThermoFisher Scientific	A32955	
Commercial assay or kit	iProof™ High-Fidelity DNA Polymerase	Bio-Rad Laboratories, Inc.	172-5301	
Commercial assay or kit	iScript gDNA Clear cDNA Synthesis Kit	Bio-Rad Laboratories, Inc.	172-5034	
Commercial assay or kit	iTaq Universal SYBR Green Supermix	Bio-Rad Laboratories, Inc.	1725120	
Commercial assay or kit	DreamTaq Green PCR	ThermoFisher Scientific	K1081	
Commercial assay or kit	DC protein assay	Bio-Rad Laboratories, Inc.	5000116	
Commercial assay or kit	NuPAGE 4-12% BisTris gels	ThermoFisher Scientific	NP0321BOX	
Commercial assay or kit	NuPAGE 3-8% TrisAcetate gels	ThermoFisher Scientific	EA0375BOX	
Commercial assay or kit	SuperSignal West Pico PLUS Chemiluminescent Substrate	Thermo Fisher Scientific	34577	
Commercial assay or kit	SuperSignal West Femto PLUS Chemiluminescent Substrate	Thermo Fisher Scientific	34095	
Commercial assay or kit	Strep-Tactin XT Superflow high-capacity resin	IBA Lifesciences	2-4030-025	Product discontinued; suitable replacement is Strep-Tactin XT

				4Flow high capacity resin (2-5030-025)
Commercial assay or kit	Wizard Plus SV Minipreps DNA Purification System	Promega	A1460	
Commercial assay or kit	TALON Metal Affinity Resin	Takara	635502	
Peptide, recombinant protein	Lysozyme	Sigma Aldrich	L6876	
Peptide, recombinant protein	<i>DpnI</i>	NEB	R0176S	
Peptide, recombinant protein	ADP-ribosyl cyclase	Sigma Aldrich	A9106	
Peptide, recombinant protein	SpCas9 Nuclease	IDT	1081058	
Recombinant DNA reagent	pET-30a(+) TIR (plasmid)	Loring et al., 2021		Referred to as pET30a ⁺ Strept-TIR-HIS in reference
Software, algorithm	Fiji/ImageJ	PMID: 22743772		
Software, algorithm	OASIS 2	PMID: 27528229		
Software, algorithm	R Console (Version 3.5)	The R Foundation		https://www.r-project.org/
Software, algorithm	FastQC (Version 0.11.5)	https://www.bioinformatics.brahaem.ac.uk/projects/fastqc/		
Software, algorithm	Kallisto (version 0.45.0)	PMID: 27043002		

Software, algorithm	Sleuth (version 0.30.0)	PMID: 28581496		
Software, algorithm	GSEA (version 4.1.0)	PMID: 16199517		
Software, algorithm	pheatmap (version 1.0.12)	https://cran.r-project.org/web/packages/pheatmap/index.html		
Software, algorithm	DAVID Bioinformatics database	PMID: 19131956		
Software, algorithm	GraphPad Prism ⁹	Graphpad		https://www.graphpad.com/scientific-software/prism/

A **B**

A **B** **C** **D** **E** **F** **G**

A **B** **C** *T24B8.5p::gfp***D****Agarose medium****0 $\mu\text{g/mL}$ cholesterol + 0.1% Tergitol** **Saturated fatty acids****Monounsaturated fatty acids** **Polyunsaturated fatty acids** *T24B8.5p::gfp*

A

**Gene set enrichment analysis:
pmk-1 dependent genes**

B **C**

**Figure 4G intestinal T24B8.5p::gfp
fluorescence quantification**

D